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Gastroesophageal reflux disease (GERD) is defined according to the Montreal 
consensus as a condition, which develops when the reflux of stomach contents 
causes troublesome symptoms and/or complications, whereby troublesome 
means that they adversely affect an individual’s well-being [1].  
From a surgical perspective, GERD is the failure of the antireflux barrier, 
caused by a defective LES, a gastric emptying disorder, or failed esophageal 
peristalsis. The abnormalities result in a spectrum of disease ranging from 
symptoms only, such as heartburn, to esophageal tissue damage with or with-
out subsequent complications including malignancy or airway disease [1]. 
Description of Technology 
Magnetic sphincter augmentation (MSA) represents a novel method for the 
surgical treatment of GERD. The magnetic sphincter augmentation device 
is a ring of magnetic beads made of titanium that is placed around the lower 
esophagus just above the stomach using laparoscopy under general anaes-
thesia. The goal of the intervention is to reinforce the weak lower esophageal 
sphincter (LES). The magnetic attraction between the beads is intended to 
help the LES resist opening to gastric pressures, preventing reflux from the 
stomach into the esophagus. 
 
Methods 
The EUnetHTA Core Model for Rapid Relative Effectiveness was the main 
source for selecting relevant assessment elements. We conducted a systemat-
ic literature search (without restriction on publication date) in bibliographic 
databases, in the Cochrane Library and in the database of the Centre for Re-
views and Dissemination, complemented by a SCOPUS hand search, to an-
swer the research questions in the domains effectiveness and safety. Selection 
of relevant documents (in English and German) was done by two persons in-
dependently. The Grading of Recommendations Assessment, Development 
and Evaluation (GRADE) methodology was used for qualitatively summaris-
ing the results for the domains: “Safety” and “Clinical effectiveness”. 
Domain effectiveness 
For analysing the clinical effectiveness, prospective controlled studies were 
included, provided that any of the defined outcomes were reported. The cru-
cial outcome to derive a recommendation was the GERD HRQL score. 
Domain safety 
For analysing the safety, prospective controlled and uncontrolled studies were 
included. The crucial outcomes to derive a recommendation were: overall 
complication rate, intraoperative complications, dysphagia, excessive bloat-
ing, device removal, migration, malfunction and erosion, re-operation rate, 
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Results 
Available evidence 
A total of 5 single-arm prospective case series and one prospective registry 
with control group were eligible for inclusion in the current report, 3 of which 
provided short (1-5.8 months) and 3 long-term (1-5 years) follow-up data. 
Overall, the safety and efficacy was evaluated in 605 and 249 patients, respec-
tively.  
Clinical effectiveness 
One study with 249 participants fulfilled the inclusion criteria. GERD HRQL 
improved from 20 to 3 points in the MSAD, and from 23 to 3.5 in the laparo-
scopic fundoplication (LF) group. Due to the major differences in the two 
study groups, no direct conclusion on relative effectiveness of MSAD in com-
parison to the alternative treatment option LF can be drawn. 
Safety 
One prospective registry with control group with 249 patients fulfilled the 
inclusion criteria for comparing dysphagia, excessive bloating, re-operation, 
hospital re-admission, and intraoperative complications. For analysing de-
vice removal, migration, malfunction, and erosion, 5 prospective case series 
and one prospective registry with control group fulfilled the inclusion crite-
ria. Dysphagia was 7% in the MSAD versus 10.6% in the LF group, exces-
sive bloating occurred in 10% of MSAD and 31.9% of LF patients, re-op-
eration rate and hospital readmission was 4% resp. 5.4% in the MSAD and 
6.4% resp. 4.3% in the LF group. Intraoperative complications occurred in 3 
patients (1.49%) in the MSAD and in 1 patient (2.13%) in the LF group. 
Device removal was reported in 4 of the case series, ranging from 0 to 7%, 
and in the registry study, with 4% of patients having the device removed.  
Upcoming evidence 
Currently, there are no registered ongoing or planned controlled trials com-
paring MSAD with LF for the treatment of GERD. 
Reimbursement 
Currently, the use of MSAD for the treatment of GERD is not reimbursed by 
the Austrian health care system. 
 
Discussion 
The available evidence for the technology is in its infancy and it is not suffi-
cient to determine the safety and effectiveness of the LINX device. Future 
clinical trials should be comparative (favourably randomised), with a broad-
er patient population. Crucial outcome measures should include the device’s 
ability to reduce the likelihood of developing GERD complications, like esoph-
ageal cancer, and the long-term safety considerations, like the durability of 
the device and late device removals.  
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Conclusion 
The current evidence is not sufficient to prove that the assessed technology, 
MSAD, is at least equally effective and as safe as the comparator LF. Com-
parative data on the two procedures are available from a single registry study 
where the LF group was in a more severe stage of the disease and neverthe-
less achieved a similar improvement in GERD related quality of life as the 
MSAD group. Concerning safety, the re-operation and hospital re-admission 
rates were similar; the difference in other complications like dysphagia was 
statistically not significant. Significant difference is only shown in inability 
to belch or vomit and in excessive bloating. 
New study results will potentially influence the effect estimate considerably 
only if they are sham control studies or RCTs comparing MSAD and LF.  
The inclusion in the catalogue of benefits is currently not recommended. 
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Zusammenfassung 
Einleitung 
Indikation und therapeutisches Ziel 
Die gastroösophageale Refluxkrankheit (GERD) ist eine häufige Erkrankung 
in den Industrieländern der westlichen Welt mit einer Prävalenz von bis zu 
15 % und einer zunehmenden Inzidenz. Aufgrund ihrer zunehmenden Häu-
figkeit beansprucht die Behandlung von GERD wachsende Ressourcen. Zu 
den beeinflussenden Faktoren für die Entwicklung von GERD zählen fal-
sche Ernährung (Fettleibigkeit, erhöhter Fettkonsum, Essen unmittelbar vor 
dem zu Bett gehen) und passiver Lebensstil (Bewegungsmangel). 
Typische Symptome von GERD sind: Sodbrennen, Aufstoßen, Magenschmer-
zen. Atypische Symptome sind: chronischer Husten, Heiserkeit, Dysphagie, 
Schmerzen in der Brust, chronische Aspiration, Bronchitis, Sinusitis. Auf 
Grundlage der Häufigkeit und Schwere der Reflux-Symptome, wird von mil-
der, moderater und schwerer GERD gesprochen, jedoch ohne explizite De-
finition über die Dauer und die Messung. 
Der natürliche Verlauf der Erkrankung ist ungeklärt. Traditionell wird die 
Krankheit als Spektrum beginnend mit nicht-erosivem Reflux (NERD), der 
sich zu GERD (erosiver Ösophagitis, Stenose, Barrett-Ösophagus) entwickelt, 
beschrieben. Das Management von GERD wird durch die Schwere der Symp-
tome bestimmt: Die Leitlinien der „American College of Gastroenterology“ 
(ACG) und der „Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen 
Fachgesellschaften“ (AWMF) schlagen ein schrittweises Vorgehen vor: Als 
erste Interventionen werden Veränderungen in der Ernährung und im Le-
bensstil vorgeschlagen.  
 Gewichtsverlust für GERD-PatientInnen, die übergewichtig sind, 
 Oberkörperhochlage und Vermeidung von Mahlzeiten 2-3 Stunden 
vor dem Zubettgehen für PatientInnen mit nächtlicher GERD,  
 bei mild bis moderater Schwere der Symptome:  
ein H2-Rezeptor-Antagonist (H2RA) Therapie, 
 wenn H2RA Therapie nicht ausreichend ist, und der/die Patientin mo-
derate bis schwere Symptome hat: Initiierung einer 8-wöchigen The-
rapie mit Protonenpumpeninhibitioren (PPI),  
 bei anhaltenden GERD Symptomen ist eine PPI-Erhaltungstherapie 
(mit niedriger Dosierung) indiziert. 
 Eine Operationsindikation ist gegeben, wenn zusätzlich zur langfris-
tigen Behandlungsbedürftigkeit folgende Indikationskriterien erfüllt 
sind: intolerable Reflux-induzierte Restbeschwerden oder eine Unver-
träglichkeit gegenüber der PPI-Therapie besteht. 
Minimal-invasive Verfahren wie der Magnetische Speiseröhren Ring (engl. 
Magnet sphincter augmentation device/MSAD) sind also Zweitlinien Behand-
lungen und erst nach Therapieversagen für chronische GERD-PatientInnen 
indiziert. Die Zielgruppe für MSAD sind erwachsenen PatientInnen mit mo-
derater bis schwerer GERD, die für die chirurgische Behandlung wegen un-
vollständiger Kontrolle der Symptome trotz maximaler medikamentöser Be-
handlung oder schweren Komplikationen im Zusammenhang mit PPI-Thera-
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Beschreibung der Technologie 
Der Magnetische Speiseröhren Ring (MSAD) ist ein neues Verfahren für die 
chirurgische Behandlung von GERD. Eine aus magnetischen Titan-Perlen 
bestehende Kette wird als Ring oberhalb des Magens um den unteren Öso-
phagus platziert. Der Magnetismus verschließt damit den Ausgang der Spei-
seröhre zum Magen. Der Magnetische Speiseröhren Ring wird im Rahmen 
einer Bauchspiegelung laparoskopisch eingesetzt: Das Gerät benötigt keine 
anatomische Veränderung des Magens. Das Ziel der Intervention ist, den un-
teren Schließmuskels der Speiseröhre zu verstärken und so den Reflux aus 
dem Magen in die Speiseröhre zu verhindern. Bei Nahrungsaufnahme kann 
die Flüssigkeit oder feste Nahrung nach dem Schlucken den Schließmuskel 
passieren, nicht jedoch zur zurückfließen. 
Derzeit gibt es nur ein MSAD (Magnet sphincter augmentation device) auf 
dem Markt, das LINX® Reflux Management System. Es wurde von Torax 
Medical Inc. entwickelt. Das Medizinprodukt LINX® befindet sich derzeit in 
der 2. Generation am Markt. Die Produkte-Generationen unterscheiden sich 
durch den Verschluss des Speiseröhren Ring um den Ösophagus, aber auch 
durch ihre MRT-Compliance: Die 2. Generation ist MRT-kompatibel (bis 
1,5 Tesla). Das LINX® Reflux Management System ist in Europa mit dem 
CE-mark (seit 2008) und in den USA durch die FDA (seit 2012) zugelassen. 
Weltweit wurden bislang ungefähr 4.000 LINX®-Systeme implantiert. 
LINX® wurde für die minimal-invasive Behandlung der chronischen gast-
roösophagealen Refluxkrankheit, die durch abnorme pH-Werte, chronische 
GERD-Symptome trotz maximaler medikamentöser Therapie gekennzeich-
net ist und für nicht operativ vorbehandelte PatientInnen > 18 Jahre, mit 
BMI ≤ 35 haben und mit einer Hiatushernie ˂ 3 cm zugelassen. Bei Hiatus-
hernie > 3cm bedarf es einer zusätzlichen klinischen Abklärung.  
Die Standardmethode zur chirurgischen Behandlung von GERD ist die (of-
fene oder laparoskopische) Fundoplikatio: zur Verhinderung eines Rückflus-
ses von Mageninhalt in die Speiseröhre wird eine Fundusmanschette um den 
abdominalen Anteil der Speiseröhre gelegt. Der Speisebrei kann weiterhin von 
der Speiseröhre in den Magen befördert werden. Die dabei entstehende Fül-
lung der Manschette komprimiert jedoch die abdominale Speiseröhre, so dass 
ein Reflux aus dem Magen in die Speiseröhre verhindert wird. Zwei Techni-
ken sind zu unterscheiden: die Nissen Fundoplikatio (derzeit Gold-Standard) 
und die partielle oder Toupet Fundoplikatio. Die Rekonvaleszenzzeit nach la-
paroskopischer Fundoplikatio beträgt 4-6 Wochen und die PatientInnen dür-
fen für etwa eine Woche nach der Operation nur flüssige Nahrung zu sich 
nehmen, bevor sie nach und nach auf weiche, dann feste Nahrung übergehen 
können. In Guidelines wird empfohlen, dass die Fundoplikatio nur in GERD-
Zentren mit hoher PatientInnen-Frequenz durchgeführt werden sollte. 
Die von LINX® erwarteten Vorteile sind geringere Invasivität des chirurgi-
schen Eingriffs und Reversibilität. Laut Hersteller ist die Operationszeit eben-
so wie die Krankenhausaufenthaltsdauer kürzer, die Operationstechnik we-
niger schwierig und damit ihre Reproduzierbarkeit höher, die Lernkurve für 
ChirurgInnen kürzer, die Nebenwirkungen geringer. Zudem wird PatientIn-
nen empfohlen, gleich nach dem Eingriff zur normalen Ernährung zurück-
kehren. Die Kosten für das LINX® Reflux Management System betragen 
zum einen die Kosten für das Medizinprodukt (4.340 €) sowie Kosten, die im 
Krankenhaus anfallen (Personal, Anästhesie, Krankenhausaufenthalt). Im 
Vergleich zur Fundoplikatio fallen Materialkosten (Medizinprodukt) und 
die Erstausbildung von ChirurgInnen an, hingegen kürzere OP-Zeiten.  
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Methoden 
Die Beantwortung der Forschungsfragen bezüglich Wirksamkeit und Sicher-
heit erfolgte anhand einer systematischen Literatursuche in folgenden Daten-
banken: 
 Medline via Ovid, 
 Embase, 
 the Cochrane Library, 
 CRD (DARE, NHS-EED, HTA) 
Zusätzlich wurde eine Handsuche durchgeführt und der Hersteller kontak-
tiert. Die Studienauswahl erfolgte unabhängig durch beide AutorInnen (JE, 
MS). Die Erstautorin (JE) extrahierte die Studiendaten und der Zweitautor 
(MS) kontrollierte die Daten. 
Die Daten der für die Entscheidung herangezogenen Endpunkte wurden aus 
den einzelnen Studien zusammengefasst und nach GRADE (Grading of Re-
commendations Assessment, Development and Evaluation) bewertet. 
Zusätzlich wurde das Bias-Risiko der Studien durch die Erstautorin (JE) be-
wertet und die Daten vom Zweitautor (MS) kontrolliert. 
Klinische Wirksamkeit 
Zur Bewertung der Wirksamkeit des LINX® Reflux Management Systems 
wurden die folgenden entscheidenden Endpunkte für eine Empfehlung her-
angezogen:  
 GERD HRQL score 
Weitere wichtige Endpunkte wurden berücksichtigt: Sodbrennen, tägliches 
Aufstoßen, extra-ösophageale Symptome, Absetzen oder Reduktion von PPI-
Medikamenten. 
GERD HRQL score: Da GERD eine degenerative Erkrankung ist, ist es das 
Ziel des Magnetische Speiseröhren Rings, den Prozess der Degeneration zu 
stoppen, die Funktion des Ösophagus-Schließmuskels zu übernehmen und 
damit die Lebensqualität zu verbessern. Der GERD HRQL score misst die 
Veränderungen in typischen GERD-Symptomen nach einer chirurgischen 
oder medizinischen Behandlung. Der GERD HRQL score enthält Fragen zu 
Sodbrennen, Schwierigkeiten beim Schlucken, Blähungen und zur Medika-
menteneinnahme. Die bestmögliche Punktezahl ist 0 (asymptomatisch), die 
schlechteste Punktezahl ist 50.  
Sicherheit 
Zur Bewertung der Sicherheit des LINX® Reflux Management Systems wurden 
die folgenden entscheidenden Endpunkte für eine Empfehlung herangezogen:  
 Dysphagie 
 Post-operative übermäßige Blähungen 
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Ergebnisse 
Wirksamkeit: Verfügbare Evidenz 
Zur Beurteilung der Wirksamkeit von MSAD in der Behandlung von GERD 
erfüllte nur eine Studie die Einschlusskriterien: eine prospektive Registerstu-
die mit Kontrollgruppe, multizentrisch (n=22), in vier Ländern. Die Kon-
trollgruppe umfasst PatientInnen, die einer laparoskopischen Fundoplikatio 
(LF) unterzogen wurden. Die klinische Studie, vom Hersteller Torax Medi-
cal Inc. gesponsert, umfasst 249 PatientInnen (202 MSAD, 47 LF) mit 1 Jahr 
Follow-up, 77 Frauen und 125 Männer.  
Die Patientencharakteristika waren in den beiden Gruppen unterschiedlich: 
LF-PatientInnen hatten schwerere GERD-Symptome in Bezug auf die Größe 
der Hiatushernien (45,7 % LF > 3 cm vs. 1,6 % MSAD). Zudem waren mehr 
PatientInnen mit Barrett-Ösophagus in der LF-Gruppe (19,1 % vs. 1,0 %) als 
in der MSAD-Gruppe und mit Ösophagitis Grad C und D (LF 8,5 % vs. 1 % 
MSAD). Der mittlere BMI-Score, die Anzahl der Jahre mit PPI-Therapie so-
wie die Anzahl der Jahre mit GERD waren dagegen ähnlich.  
Diese genannten Unterschiede sind insofern bedeutsam, als sie Anzeichen von 
fortgeschrittener GERD sind, für die MSAD nicht indiziert ist. 
In der Registerstudie zeigten sich folgende Ergebnisse:  
 Sodbrennen verbesserte sich vom Ausgangswert bei 30,8 % der MSAD 
PatientInnen auf 3,5 % vs. 40 % der LF-PatientInnen auf 8,5 % nach 
einem Follow-up von 1 Jahr. 
 Aufstoßen verbesserte sich von 58,2 % der MSAD PatientInnen auf 
3,1 % vs. 60 % der LF-PatientInnen auf 13 %. 
 Extra-ösophageale Symptome wurden vor der Intervention bei 63,9 % 
der MSAD PatientInnen beobachtet, danach bei 22,3 % vs. 53,3 %/ 
17,4 % in der LF-Gruppe. 
 Absetzen der PPI-Medikamente: 81,8 % der PatientInnen mit MSAD 
setzten die PPI-Therapie ab vs. 63 % der PatientInnen in der LF-
Gruppe. 
 Im GERD HRQL score zeigten MSAD PatientInnen eine Verbesserung 
von 20 auf 3 Punkte vs. von 23 auf 3,5 bei LF-PatientInnen. 
 Patientenzufriedenheit: 91,8 % der MSAD PatientInnen vs. 86,7 % der 
LF-PatientInnen zeigten sich beim Follow-up zufrieden. 
Sicherheit 
Zur Beurteilung der Sicherheit vom MSAD in der Behandlung von GERD 
erfüllten sechs Studien die Einschlusskriterien: fünf prospektive Fallserien 
und die schon zur Wirksamkeitsbeurteilung herangezogene prospektive Re-
gisterstudie mit Kontrollgruppe. Insgesamt wurden Ergebnisse von 356 Pa-
tientInnen in den fünf prospektiven Fallserien – alle vom Hersteller Torax 
Medical Inc. gesponsert – berichtet (144 Frauen und 212 Männer) sowie von 
249 PatientInnen (davon 202 mit MSAD: 77 Frauen und 125 Männer) in der 
prospektiven Registerstudie. Wegen einer hohen Wahrscheinlichkeit von Dop-
pelpublikation einzelner PatientInnen liegt die Gesamtzahl der PatientInnen, 
die (in den Studien) einer MSAD Operation unterzogen wurden, zwischen 
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Die Charakteristika der eingeschlossenen PatientInnen zeigten eine gewisse 
Heterogenität in Bezug auf Alter, Dauer der GERD-Symptome, PPI Therapie-
ansprechen etc.. Das Alter rangierte zwischen 18 und 86, drei Studien schlos-
sen nur PatientInnen mit GERD-Symptome ≥ mindestens 6 Monate ein; die 
durchschnittliche Anzahl der Jahre mit GERD wurde in vier Studien mit 4-
10 Jahren angegeben; die durchschnittliche Anzahl der Jahre mit PPI-Me-
dikamentierung wurde in vier Studien mit 1-6,3 Jahren berichtet.  
Nur die Registerstudie ermöglicht einen Vergleich zur Fundoplikatio bei Dys-
phagie, übermäßigen Blähungen, Unfähigkeit zu Rülpsen oder Erbrechen, in-
traoperativen Komplikationen, Re-Operationen und Re-Hospitalisierungen. 
Die Ergebnisse der Registerstudie berichten:  
 Postoperative übermäßige Blähungen kamen bei 10 % der MSAD  
PatientInnen vs. 31,9 % der LF-PatientInnen vor. 
 Bei intraoperativen Komplikationsrate (1,49 % bei MSAD vs. 2,13 % 
in LF-PatientInnen) war kein signifikanter Unterschied zwischen den 
beiden Gruppen. 
 1,6 % der MSAD PatientInnen vs. 10,1 % der LF PatientInnen  
konnten nicht rülpsen. 
 8,7 % der MSAD PatientInnen vs. 56,6 % der LF PatientInnen  
konnten nicht erbrechen. 
 7 % der MSAD Patientinnen vs. 10,6 % der LF-PatientInnen hatten 
Dysphagie nach 1 Jahr Follow-up.  
 4 % der MSAD PatientInnen vs. 6,4 % der LF-PatientInnen wurden 
re-operiert, um das Medizinprodukt wieder zu entfernen (MSAD) oder 
die Fundusmanschette zu adjustieren (LF).  
 5,4 % der MSAD PatientInnen vs. 4,3 % des LF-Innen wurden 
nochmals ins Krankenhaus aufgenommen (re-hospitaisiert). 
Entfernen des Medizinprodukts, Erosion, Migration und Fehlfunktionen wur-
den in den Fallserien sowie der Registerstudie berücksichtigt: 
 Produktentfernung wurde in fünf Studien berichtet: zwei Studien mit 
Follow-up bis zu 1 Jahr zeigten 0 % Explantationen; drei Langzeit-
studien (Follow-up 1 bis 5 Jahre) zeigten eine Entfernungsrate von 4 % 
nach 1 Jahr Follow-up; 3 % nach drei Jahren Follow-up und 7 % nach 
fünf Jahren Follow-up.  
 Erosion und Migration wurde in drei Studien berichtet: es trat in 
keiner ein Produktedefekt/Entriegelung auf. 
Laufende Studien 
Derzeit gibt es keine registrierten laufenden oder geplanten kontrollierten 
Studien die LINX® mit LF vergleichen. Eine laufende klinische Studie ver-
gleicht LINX® mit Omeprazole (PPI); zwei weitere Studien haben keine Kom-
paratoren: eine erprobt LINX® an einer neuen Patientengruppe (GERD-Pa-
tientInnen, die sich zuvor einer laparoskopischen „Sleeve Gastrectomy“ gegen 
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Kostenerstattung 
Im Jahr 2014 wurde in Österreich die Medizinische Einzelleistung LM030 
(offene Fundoplikatio/Hiatusplastik) 98-mal, LM040 (laparoskopische Fund-
oplikatio/Hiatusplastik) 1723-mal abgerechnet. Das LINX® Reflux Manage-
ment System wird bislang nicht erstattet, derzeit aber bereits in sechs Zen-
tren – nach Angaben des Herstellers – implantiert. 
 
Diskussion 
Der Magnetische Speiseröhren Ring ist ein relativ neuer Eingriff und es lie-
gen nur wenige Daten über die klinische Wirksamkeit und Sicherheit des Ver-
fahrens vor. Alle vorliegenden Studien wurden vom Produktehersteller ge-
sponsert, Mehrfachpublikation von PatientInnen ist sehr wahrscheinlich. 
MSAD erhielt 2008 die Europäische Marktzulassung und 2012 die FDA-Zu-
lassung basierend auf 2 Jahres-Follow-up-Daten. Die für die FDA-Zulassung 
post-marketing 5 Jahres Follow-up-Daten sind in der vorliegenden Bewertung 
einbezogen.  
Für die Beurteilung des LINX® wurde die best-verfügbare Evidenz herange-
zogen: eine prospektive Registerstudie mit Kontrollgruppe für die Beurtei-
lung der Wirksamkeit, fünf (weitere) prospektive Fallserien für die Beurtei-
lung der Sicherheit. Robuste klinische Daten aus (randomisierten) kontrol-
lierten Studien zum Vergleich mit dem Gold-Standard Fundoplikatio liegen 
nicht vor und werden auch in naher Zukunft nicht vorliegen, da keine lau-
fenden Studien registriert sind. Die Registerstudie zeigte bei einem Follow-
up von 1 Jahr sehr ähnliche Ergebnisse zwischen den Gruppen. Wichtig ist, 
dass die Studie mit 5-jährigem Follow-up ein Wiederauftreten der Krankheit 
zeigte: Sodbrennen verbesserte sich bei 89 % der PatientInnen auf 3,2 % im 
ersten Jahr, nahm im zweiten Jahr auf 5,6 % zu, 8 % im dritten Jahr, 9,3 % 
im vierten Jahr und 11,9 % im fünften Jahr. 
Die berichteten Ergebnisse zu den Wirksamkeits- und Sicherheitsendpunk-
ten (Aufstoßen, extra-öophageale Symptome, Absetzen der PPI-Therapie, 
GERD HRQL und die allgemeine Zufriedenheit) zeigen Homogenität zwi-
schen dem Register und den Fallserien. Wichtig ist aber, dass die Ergebnisse 
aus den Fallserien nicht nur den Ergebnissen aus der Registerstudie ähneln, 
sondern auch den Ergebnisse aus LF-Studien. Alle diese Ergebnisse haben 
leichte bis deutliche Verbesserung, sowohl in den einarmigen Studien wie in 
der Register-Studie gezeigt. Beide Gruppen in der Registerstudie hatten ähn-
liche Ergebnisse mit einer Ausnahme: 81,8 % der MSAD PatientInnen konn-
ten die PPI-Therapie absetzen im Vergleich zu 63 % der LF-PatientInnen. 
Nur beim Endpunkt Dysphagia zeigten sich in den Fallserien keine einheit-
lichen Ergebnisse. Ergebnisse zur Sicherheit von MSAD basieren auf allen 
sechs prospektive Studien und zeigen die relative Sicherheit des Medizin-
produkts; jedoch sind die postoperativen Nebenwirkungen im Vergleich zu 
LF aufgrund der unterschiedlichen Schwere der Erkrankung in den beiden 
Patientengruppen nicht direkt vergleichbar.  
Nichtsdesto weniger sind die vom Hersteller genannten wichtigsten Vorteile 
des MSAD Verfahrens, dass es weniger invasiv und reversibel ist, dass es 
kürzere Krankenhausaufenthalte bedarf und eine schnellere Rückkehr zur 
normalen Ernährung ermöglicht. Offene Fragen bleiben bez. Langzeitsicher-
heit von MSAD aufgrund zunehmender Explantationen bei längerem Follow-
up. 
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Die methodischen Einschränkungen der Studien sind der unklare Auswahl-
prozess der PatientInnen, nicht-konsekutive Rekrutierung der Studienteil-
nehmerInnen, Unklarheit, ob die Studienteilnahme zu einem ähnlichen Zeit-
punkt in der Erkrankung stattfand etc.. Alle Wirksamkeits-ergebnisse waren 
„patient-reported-outcomes“, und unterliegen daher (weil unverblindet) ei-
nem hohen Risiko für Bias. 
Unsicherheit kommt auch von der Ambivalenz der Therapieoptionen: Einer-
seits wird LF als Alternative vorgestellt, andererseits will MSAD die „thera-
peutische Lücke zwischen PatientInnen, die mit PPI Behandlung unzufrie-
den sind und diejenigen, die zögern, sich einer Fundoplikatio zu unterzie-
hen“ füllen. Die Zielpopulation von MSAD scheint jedenfalls die weniger 
schwer von GERD betroffenen PatientInnen zu sein. Eine laufende Studie 
vergleicht MSAD mit PPI, eine weitere untersucht voroperierte PatientInnen. 
Vor diesem Hintergrund wäre nicht ein RCT mit MSAD vs. LF, sondern ein 
RCT mit sham-Intervention notwendig, um die Wirksamkeit von MSAD zu 
bestätigen. In Ermangelung klarer Einstufungen von Schweregraden besteht 
die Gefahr der Indikationsausweitung. 
Es gibt einige andere „emerging“ Technologien, die die oben genannte the-
rapeutische Lücke zu füllen versuchen. Diese lassen sich in drei Gruppen 
einteilen: 
1. Radiofrequenzablation des LES (Stretta System), 
2. Transoral Incisionless Fundoplikatio (TIF), 
3. Elektrische Stimulationstherapie des unteren Schließmuskels  
der Speiseröhre (LES-EST). 
Unbehandelter chronischer Reflux kann zu Folgeerkrankungen wie Progres-
sion der GERD zu erosiver Ösophagitis, Ösophagusstriktur, Barrett-Ösopha-
gus oder sogar Speiseröhrenkrebs führen, weshalb die Wirkung von MSAD 
auf die Verhinderung dieser Erkrankungen auch analysiert werden müssen. 
Auch müssen potentielle Einsparungen durch die Reduktion oder Verhinde-
rung einer teuren PPI-Therapie den Kosten dieses minimal-invasiven Ein-
griffs gegenübergestellt werden. Darüber hinaus können langfristige PPI-The-
rapien schwere Nebenwirkungen wie Verringerung der Kalziumabsorption, 
Osteoporose, Clostridium difficile-Infektion, etc. und Wechselwirkungen mit 
anderen Medikamenten nach sich ziehen.  
 
Empfehlung 
Die aktuelle Evidenz ist nicht ausreichend, um zu beweisen, dass die Tech-
nologie MSAD gleich wirksam und weniger sicher ist als der Komparator 
Fundoplikatio. Vergleichsdaten über die beiden Verfahren stehen aus einer 
einzigen Registerstudie mit Kontrollgruppe zur Verfügung: die LF-Gruppe 
befand sich allerdings in einem schwereren Stadium der Erkrankung und er-
zielte dennoch eine ähnliche Verbesserung in der GERD bezogenen Lebens-
qualität wie die MSAD PatientInnen. In Bezug auf die Sicherheitsendpunkte 
waren die Re-Operations- und Rehospitalisierungsraten ähnlich. Das Vertrau-
en in diese vergleichenden Ergebnisse ist allerdings aufgrund des Studien-
designs (Beobachtungsstudie), die begrenzte Anzahl von PatientInnen (249: 
202 MSAD vs. 47 LF) sowie die Unterschiede in den Eigenschaften der Pa-
tientInnen in den beiden Studiengruppen eingeschränkt.  
Die Ergebnisse aus qualitativ hochwertigen kontrollierten Studien können 
die Effektschätzung erheblich beeinflussen. Die Aufnahme in den MEL-Leis-
tungskatalog wird derzeit nicht empfohlen. 
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1 Scope 
1.1 PICO question 
Is insertion of a magnetic sphincter augmentation device in comparison to 
the standard surgical treatments (Nissen fundoplication, partial or Toupet 
fundoplication) in patients with gastroesophageal reflux disease more effec-
tive or equally effective concerning improvement in GERD-Health-related 
quality of life, and discontinuation or reduction of anti-reflux medication 
(proton pump inhibitors), and safer regarding the post-operative side effects 
and serious adverse events? 
 
 
1.2 Inclusion criteria 
Inclusion criteria for relevant studies are summarized in Table 1-1. 
Table 1-1: Inclusion criteria 
Population Second-line treatment for adult patients with chronic (>6 months) GERD diagnosed based 
on abnormal ambulatory pH study, endoscopic esophagitis, typical symptoms of GERD 
(heartburn or regurgitation), and at least partial response to a therapeutic trial of a proton 
pump inhibitor. Moderate to severe symptom chronic GERD and refractory GERD were 
considered in this assessment.  
International classification of diseases (ICD)-10-CM code:  
K21.9 Gastroesophageal reflux disease without esophagitis 
MeSH-term: C06.405.117.119.500.484 Gastroesophageal reflux 
Intervention Insertion of a magnetic sphincter augmentation device (MSAD) through laparoscopic surgery. 
Product name: LINX® Reflux Management System 
Comparator1 Standard surgical treatment of GERD: Nissen fundoplication, partial or Toupet fundoplication 
MeSH-term: E04.210.390 Fundoplication 
Outcomes  
Efficacy Clinical endpoint: 
 GERD-Health-related quality of life (HRQoL) 
Intermediate outcomes: 
 Heartburn 
 Daily regurgitation 
 Dysphagia 
 Excessive bloating 
 Extra-esophageal symptoms 
 Discontinuation of antireflux medication (Proton Pump Inhibitors/PPIs) 
 
                                                             
1 Comparator was selected based on recommended surgical treatment option in the 
Austrian/German guidelines for management of GERD. Fundoplication is currently 
the standard surgical treatment of GERD. There are other alternative treatments, 




für relevante Studien 
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Safety Adverse device effects (ADE), serious adverse device effects (SADE): 
 Dysphagia 
 Excessive bloating 
 Inability to belch or vomit 
 Device migration 
 Device erosion 
 Device malfunction 
 Device removal 
 Re-hospitalisation  
 Re-operation  
Study design  
Efficacy Randomised controlled trials 
Prospective non-randomised controlled trials 
Safety Randomised controlled trials 
Prospective non-randomised controlled trials 
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2 Methods 
2.1 Research questions 
Description of the technology 
Element ID Research question 
B0001 What is magnetic sphincter augmentation (MSA) and the alternative standard  
treatment option(s)? 
A0020 For which indications has the magnetic sphincter augmentation device (MSAD) received 
marketing authorisation or CE marking? 
B0002 What is the claimed benefit of MSAD in relation to the alternative standard treatment option? 
B0003 What is the phase of development and implementation of MSAD and the alternative  
standard treatment option? 
B0004 Who administers MSAD and fundoplication and in what context and level of care  
are they provided? 
B0008 What kind of special premises are needed to use MSAD and the alternative standard 
treatment option? 
B0009 What supplies are needed to use MSAD and the alternative standard treatment option? 
A0021 What is the reimbursement status of MSAD? 
 
Health problem and Current Use 
Element ID Research question 
A0001 For which health conditions, and for what purposes is MSAD used? 
A0002 What is the disease or health condition in the scope of this assessment? 
A0003 What are the known risk factors for gastrooesophageal reflux disease (GERD)? 
A0004 What is the natural course of GERD? 
A0005 What is the burden of GERD for the patients with the disease or health condition? 
A0006 What are the consequences of GERD for the society? 
A0024 How is GERD currently diagnosed according to published guidelines and in practice? 
A0025 How is GERD currently managed according to published guidelines and in practice? 
A0007 What is the target population in this assessment?  
A0023 How many people belong to the target population? 
A0011 What is the expected annual utilisation of MSAD? 
 
Clinical Effectiveness 
Element ID Research question 
D0005 How does MSAD affect heartburn, regurgitation, and extraesophageal symptoms? 
D0006 How does MSAD affect the continuation with PPI therapy? 
D0011 What is the effect of MSAD on dysphagia and bloating? 
D0016 How does MSAD affect activities of daily living? 
D0013 What is the effect of MSAD on disease-specific quality of life? 
D0017 Was the use of MSAD worthwhile? 
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Safety 
Element ID Research question 
C0008 How safe is MSAD in comparison to LF? 
C0004 How does the frequency or severity of harms change over time or in different settings? 
C0005 What are the susceptible patient groups that are more likely to be harmed through  
the use of the technology? 
C0007 Are MSAD and LF associated with user-dependent harms? 




Description of the technology 
 Handsearch in the POP, AdHopHTA and CRD databases  
for Health Technology Assessments 
 Background publications identified in database search: see Section 2.3 
 Documentation provided by the manufacturer 
 Questionnaire completed by the submitting hospitals  
Health problem and Current Use 
 Handsearch in the POP, AdHopHTA and CRD databases  
for Health Technology Assessments 
 Background publications identified in database search: see Section 2.3 
 Documentation provided by the manufacturer 
 Questionnaire completed by the submitting hospitals  
 
 
2.3 Systematic literature search 
The systematic literature search was conducted 11th-16th December 2015  
in the following databases:  
 Medline via Ovid 
 Embase  
 The Cochrane Library 
 CRD (DARE, NHS-EED, HTA) 
 PubMed 
The systematic search was (in Medline, Embase and PubMed) limited to Clin-
ical Trials and Systematic Reviews/Meta Analyses. After deduplication, 214 
citations remained for abstract screening. The systematic search was com-
plemented by a Scopus search (citation tracking) conducted on 11.02.2016, 
which yielded a further 46 unique citations. Through hand searching another 
12 references could be identified. One publication was supplied by Industry, 
bringing the total number of included citations to 273. The specific search 
strategies can be found in the Appendix.  
Quellen 
systematische 
Literatursuche in  
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2.4 Flow chart of study selection 
Overall 273 hits were identified. The references were screened by two inde-
pendent researchers and in case of disagreement a third researcher was in-
volved to solve the differences. The selection process is displayed in Figure 2-1. 
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 Background literature 
(n=29) 
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 Double reporting (n=6) 
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 NRCTs (n=0) 
 Case-series (n=6) 
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2.5 Analysis 
The data retrieved from the selected studies (see Chapter 2.4) were systemat-
ically extracted into a data-extraction-table (see Appendix Table A-1 and Ta-
ble A-2). No further data processing (e.g. indirect comparison) was applied. 
The studies were systematically assessed for quality and risk of bias using the 




Based on the data-extraction-table (see Appendix), data on each selected out-
come category were synthesised across studies according to GRADE (Grad-
ing of Recommendations Assessment, Development and Evaluation) [2]. The 
research questions were answered in plain text format with reference to GRADE 
evidence tables (see Table 7-1). 
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3 Description and technical 
characteristics of technology 
Features of the technology and comparators 
B0001 – What is magnetic sphincter augmentation (MSA) and  
the alternative standard surgical treatment(s)? 
Magnetic sphincter augmentation represents a novel method for the surgical 
treatment of GERD. The magnetic sphincter augmentation device is a ring 
of magnetic beads made of titanium that is placed around the lower esopha-
gus, just above the stomach, using laparoscopy under general anaesthesia. The 
goal of the intervention is to reinforce the weak lower esophageal sphincter 
(LES). The magnetic attraction between the beads is intended to help the LES 
resist opening to gastric pressures, preventing reflux from the stomach into 
the esophagus. Swallowing forces temporarily break the magnetic bond, al-
lowing food and liquid to pass normally into the stomach. The magnetic at-
traction of the device closes the LES immediately after swallowing, restoring 
the body’s natural barrier to reflux [3]. 
 
Figure 3-1: Operation principles of the MSAD 
The device does not require any anatomic alteration of the stomach. It is im-
planted under general anaesthesia, using a minimally invasive surgical tech-
nique called laparoscopy. In order to select the right size for the LINX de-
vice, the esophagus is measured by placing a sizing tool around the esopha-
geal tube at the LES and measuring the circumference to get the best fit. 
The measurement tool is then removed and the LINX device is positioned 
around the LES using suture tails. The ends of the device are aligned and 
joined for secure closure [3].  
 
Figure 3-2: Operation procedure of MSAD 
neue Verfahren in 
Antireflux Chirurgie: 
magnetische 
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Marketed products 
There is currently only one MSAD on the market, the LINX® Reflux Man-
agement System. It has been developed by Torax Medical Inc. [3]. The LINX 
device has two generations. The first-generation device used a Ti-Knot Re-
placement System (LSI Solutions) to secure the ends of the device around the 
esophagus. The second-generation device is the same as the first-generation 
device, except that the ends of the device are secured with a clasp instead of 
suture. Additionally, sizing of the esophagus with the first-generation device 
used a color-coded sizing device of connected beads. With the introduction of 
the second-generation device, a laparoscopic sizing tool was introduced. The 
principles of sizing the esophagus remained the same, with the only difference 
being the tool used [4].  
The other difference between the two generations is the MRI compliance. The 
first-generation device is MRI conditional only up to 0.7 tesla. Patients im-
planted with this device (before May 22, 2015) cannot undergo MRI above 
0.7 tesla. The second generation is compatible with MRI up to 1.5 tesla. The 
new system is compatible with MRI systems because it contains a different 
grade of magnets that have a higher resistance to being demagnetized when 
subjected to external magnetic fields. Torax announced the FDA approval for 
the second generation of LINX with MRI compatibility in June 2015 [5, 6]. 
Correspondence with Torax Medical Inc. indicated that approximately 4000 
LINX systems have been implanted to date worldwide.  
Table 3-1: Device generations of LINX® 
Device generations Device ends securing Sizing tool MRI compliance Implanted until 
1st generation Ti-Knot Replacement 
System (suture) 
Color-coded tool of 
connected beads 
Up to 0.7 tesla May 22, 2015 
2nd generation clasp Laparoscopic sizing tool Up to 1.5 tesla To present 
 
Current technology 
Standard surgical treatment means wrapping the fundus of the stomach around 
the esophagus to create a new valve at the level of the esophagogastric junction, 
a technique called fundoplication. Options include Nissen fundoplication and 
partial or Toupet fundoplication.  
 Nissen fundoplication is currently the gold-standard and most com-
mon surgical treatment with around an annual 2000 procedures carried 
out in Austria. It was first performed by Dr. Rudolph Nissen in 1955 
by an open technique, but is now typically carried out laparoscopical-
ly, because high-quality evidence suggests its superiority to open sur-
gery concerning early outcomes (hospital stay, fewer complications) 
with no significant differences in late outcomes, although the reoper-
ation rate is higher in the short-term [1, 7]. It is a complete or total 
wrap that encompasses 360° of the esophagus in a posterior fashion.  
 Partial fundoplication has two versions, but only one is recommended 
for the treatment of GERD, i.e Toupet fundoplication (posterior wrap), 
which covers roughly 270° of the posterior esophagus [7]. Partial fun-
doplication is associated with less post-operative dysphagia, fewer re-
operations, and its effectiveness is similar in controlling GERD symp-
toms compared to total fundoplication up to five years after surgery. 
However, there are concerns about the long-term effectiveness of par-
tial fundoplication [1]. 
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Laparoscopic fundoplication is technically difficult and it may be performed 
differently by different surgeons, which has a high impact on patient out-
comes. Although the most common is a loose (floppy) Nissen fundic wrap 
including a posterior hiatal hernia repair, the surgery technique has yet to 
be standardized to improve patient outcomes. 
The recovery time can be 4-6 weeks in fundoplication, and patients need to 
be on a pure liquid diet for one week after surgery before they can gradually 
start a soft food diet [8]. 
Hiatal hernia and its repair  
The esophagus passes through an opening in the diaphragm (the oesophage-
al hiatus) before it joins the stomach. If the stomach slips through the dia-
phragm into the chest, a condition called hiatus hernia develops. Hiatus her-
nia might be a cause of GERD [9], therefore, depending on its size, it is often 
repaired (posterior crural repair) at the time of anti-reflux surgery at the sur-
geons’ discretion to ensure the success of the anti-reflux surgery. A sliding 
hernia of up to 3 cm can be effectively repaired by approximating the crura 
with interrupted stiches [10].  
Hiatal hernia repair can be done in both interventions. Fundoplication allows 
for a concurrent hiatal hernia repair. It is recommended for those who have 
a hiatal hernia >2 cm or if someone has a gastroesophageal junction in the 
chest [8].  
A0020 – For which indications has the magnetic sphincter augmentation 
device (MSAD) received marketing authorisation or CE marking? 
LINX device received CE marking in 2008 for the minimally invasive treat-
ment of chronic gastroesophageal reflux disease (GERD), as defined by ab-
normal pH testing, for patients who continue to have chronic GERD symp-
toms despite maximum medical therapy, patients who are >18 years, have a 
BMI≤35, have not had an operation of the esophagus, or of the gastrointes-
tinal tract, have a normal motility, have no strictures, varices, achalasia or eo-
sinophile esophagitis, have had no significant psychological disorders, the 
maximum level of esophagitis is grade A or B, or have regurgitation. Patients 
with a hiatal hernia >3 cm are subject to evaluation based on the severity of 
their symptoms and the clinical picture [3]. The LINX device has FDA ap-
proval since 2012 for the same indications [11].  
B0002 – What is the claimed benefit of MSAD  
in relation to the alternative standard surgical treatments? 
The claimed major benefits of MSAD are its lesser invasiveness and reversi-
bility [12]. Insertion of the device requires little dissection and few steps, 
therefore the operative time is shorter. The operation technique is less diffi-
cult, hence its reproducibility is higher and the learning curve for the sur-
geon is also shorter [1, 13].  
MSA procedure can be associated with fewer side-effects and a shorter hos-
pital length of stay. Patients are advised to return to normal diet right after 
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B0003 – What is the phase of development and implementation  
of MSAD and the alternative standard surgical treatments? 
MSAD was first implanted in a clinical setting in 2007 in the clinical feasi-
bility study of 44 patients (NCT01058070). It is a novel technology that is still 
in its emerging phase, hence it is not a standard clinical practice yet. The 
current device is the second generation, which is MRI compatible up to 1.5 
tesla MRI compared to the first generation device, which can be used up to 
0.7 tesla. Current clinical trials are investigating the use of the device in other 
subgroups of GERD patients (after laparoscopic sleeve gastrectomy) that had 
been so far excluded from the use of the device. New versions of the device 
with substantial improvements are not expected in the near future. 
Fundoplication was first performed in 1955 and has become the standard sur-
gical anti-reflux treatment. It has several modifications, of which two (Nissen 
and Toupet) are the most commonly used and accepted in clinical practice. 
 
Administration, Investments, personnel and  
tools required to use the technology and the comparator(s) 
B0004 – Who administers MSAD and fundoplication and  
in what context and level of care are they provided? 
B0008 – What kind of special premises are needed to use MSAD  
and fundoplication? 
B0009 – What supplies are needed to use MSAD and fundoplication? 
Both MSA and laparoscopic fundoplication is performed under general an-
aesthesia by a foregut surgeon. The guidelines suggest that fundoplication is 
done in high-volume centres by experienced foregut surgeons. Surgeons with 
little experience should have expert supervision during their early experience 
with the procedure to minimize morbidity and improve patient outcomes [1].  
The premises, the operation team, and the supplies are similar, the only dif-
ference being the device itself along with the sizing tool to determine the in-
dividual device size needed.  
 
Regulatory & reimbursement status  
A0021 – What is the reimbursement status of MSAD? 
According to the submission documents received from the Austrian Ministry 
of Health (MoH), MSAD is currently not included in the Austrian catalogue 
of benefits. The costs associated with the MSA operation include the price of 
the device, the sizing tool (€ 4,240 and € 100 respectively), and the operation 
procedure (facilities, staff, anaesthesia, hospital stay). The information about 
the former two has been provided by the manufacturer.  
In comparison to fundoplication, the material costs (device and sizing tool) 
and the initial training of surgical staff to undertake the implantation proce-
dure are additional to the costs of the operation procedure, although the pro-
cedure itself might cost slightly less due to its shorter operation time. The 
LINX® device is in the German and Swiss DRG-Systems and is reimbursed 
up to the amount of € 8,100. In Austria, there are currently 6 centres where 
the LINX System is available, but according to the manufacturer, in 2016, this 
number is increasing to 10-15.  
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4 Health Problem and Current Use 
Overview of the disease or health condition 
A0001 – For which health conditions, and for what purposes  
is MSAD used? 
A0002 – What is the disease or health condition  
in the scope of this assessment?  
MSAD is used in patients with GERD, which is defined according to the Mon-
treal consensus as a condition that develops when the reflux of stomach con-
tents causes troublesome symptoms and/or complications. Symptoms are con-
sidered troublesome if they adversely affect an individual’s well-being [1]. 
MSAD is a second-line treatment for GERD patients in whom PPI medica-
tion failed to achieve complete symptom alleviation, symptoms recur despite 
initial successful medication, and for those who refuse to take life-long med-
ication or suffer from side-effects of PPI therapy. The main aim of MSA is 
the alleviation of symptoms by strengthening the weak LES, the anatomical 
cause of GERD. MSAD is not curative, long-term (life-long) use is essential 
to maintain the treatment effect.  
From a surgical perspective, GERD is the failure of the antireflux barrier al-
lowing abnormal reflux of gastric contents into the esophagus. It is a mechani-
cal disorder, which is caused by a defective LES, a gastric emptying disorder, 
or failed esophageal peristalsis. The abnormalities result in a spectrum of 
disease ranging from symptoms only, such as heartburn, to esophageal tissue 
damage with or without subsequent complications, including malignancy or 
airway disease [1]. 
Reflux can be categorized based on symptoms or based on its nature.  
Symptom based approach differentiates between typical and atypical  
symptoms: 
 Typical symptoms: heartburn, regurgitation, epigastric pain. 
 Atypical symptoms: chronic cough, hoarseness, globus, dysphagia, 
chest pain, chronic aspiration, bronchitis, sinusitis.  
Based on its nature, GERD can be acid or non-acid.  
 Acid reflux with a pH<4.0 
 Non-acid reflux with a pH>4.0 
Non-acid reflux is poorly understood yet [8]. 
A generally accepted definition on the severity of GERD is lacking. Based on 
the frequency and severity of the experienced reflux symptoms, the expres-
sions used in the literature spread from mild, through moderate, to severe 
GERD, however, without any explicit definition about the duration and the 
measurement of them.  
A0003 – What are the known risk factors  
for gastro esophageal reflux disease (GERD)? 
There are anatomical and patient factors that can contribute to the develop-
ment of reflux. The anatomical factors are related to the LES, the diaphrag-
matic crura, and the phrenoesophageal ligament. The patient factors include 
diet and lifestyle, as well as obesity. Eating refluxogenic foods, overeating, 
eating immediately before going to bed, increased fat consumption in the diet, 
GERD:  
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and expanding proportion of obese individuals are significant risk factors for 
GERD. In obese patients, the intra-gastric pressure and the frequency of tran-
sient LES relaxations is chronically increased, which is thought to be the cause 
of GERD [8, 14].  
A0004 What is the natural course of GERD? 
The natural history of the disease has not been well clarified yet. Currently 
two concepts exist: 
 The traditional concept sees the disease as a spectrum starting with 
non-erosive reflux disease (NERD) that might progress to complicated 
GERD (erosive esophagitis, stricture, Barrett’s esophagus). This con-
cept focuses on esophageal mucosal injury as the most significant clin-
ical outcome in GERD. Patients with severe esophagitis are at high 
risk of developing a stricture and long-standing reflux symptoms are 
a major risk for developing a BE. Patients with BE have an increased 
risk of esophageal adenocarcinoma with an incidence of 40 times great-
er than in the general population (14). 
 The new concept considers GERD as a categorical disease with three 
distinct entities: NERD, erosive esophagitis, and Barrett’s esophagus 
(BE). According to this concept, these are different disorders and the 
movement among them is limited. This concept focuses on mechanisms 
leading to symptom generation rather than mucosal injury. Some stud-
ies suggest that GERD is a chronic disease, but not progressive, how-
ever other studies confirm that progression of NERD to erosive esoph-
agitis is possible in 10% of GERD patients [14]. 
These two concepts have in common that NERD might progress to GERD; 
it is debated though to what extent.  
 
Effects of the disease or health condition  
on the individual and society 
A0005 – What is the burden of disease for patients with GERD? 
Quality of life is impacted through GERD symptoms such as heartburn, ex-
tra-esophageal (pulmonary or ear, nose, throat) manifestations, or non-cardiac 
chest pain [15].  
Patients often complain about sleep disturbance. Their diet is also affected 
as the foremost treatment suggested is life-style and diet modification. Pre-
sumably, they also need to take life-long medication, which might have seri-
ous side effects, be not well tolerated, or alter the absorption of minerals and 
vitamins, have metabolic effects on bone density, pharmacokinetics or phar-
macodynamics and related drug interactions and effects, enhance infection 
risk and hypersensitivity response with consequent organ damage [12].  
A0006 – What are the consequences of GERD for the society? 
Due to its increasing incidence (approximately 5 per 1000 person-years in 
the Western world [16]) GERD is leading to a growing utilisation of health 
resources (medical consultations, emergency room visits, hospitalization, and 
medication). Not only the doctor visits and diagnosis have high financial ex-
penses, but also the medication in the long run and the operation [17]. 
The burden of disease on the individual affecting work productivity results 
in substantial societal burden and employer costs [12].  
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Current clinical management of the disease or health condition 
A0024 – How is GERD currently diagnosed according  
to published guidelines and in practice? 
According to the American College of Gastroenterology (ACG) and the Ar-
beitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaf-
ten (AWMF) Guidelines [18, 19], the recommendations for the diagnosis of 
GERD (along with the level of evidence and the level of strength of the rec-
ommendation) are the following: 
 A presumptive diagnosis of GERD can be established in the setting of 
typical symptoms of heartburn and regurgitation. Empiric medical 
therapy with a PPI is recommended in this setting (strong recommen-
dation, moderate level of evidence). 
 Patients with non-cardiac chest pain suspected due to GERD should 
have diagnostic evaluation before institution of therapy (conditional 
recommendation, moderate level of evidence). A cardiac cause should 
be excluded in patients with chest pain before the commencement of 
a gastrointestinal evaluation (strong recommendation, low level of ev-
idence). 
 Upper endoscopy is recommended in the presence of alarm symptoms 
and for screening of patients at high risk for complications (strong re-
commendation, moderate level of evidence). 
 Ambulatory esophageal reflux monitoring is indicated before consid-
eration of endoscopic or surgical therapy in patients with NERD, as 
part of the evaluation of those patients refractory to PPI therapy and 
in situations when the diagnosis of GERD is in question (strong rec-
ommendation, low level evidence). Ambulatory reflux monitoring is 
the only test that can assess reflux symptom association (strong rec-
ommendation, low level of evidence). 
A0025 – How is GERD currently managed according  
to published guidelines and in practice? 
The management of GERD is aligned with the severity of symptoms. The ACG 
and AWMF Guidelines [18, 19] suggest a stepwise approach, which starts with 
lifestyle modifications, including: 
 Weight loss for GERD patients who are overweight or have had recent 
weight gain (conditional recommendation, moderate level of evidence). 
 Head of bed elevation and avoidance of meals 2-3 hours before bed-
time for patients with nocturnal GERD (conditional recommendation, 
low level of evidence). 
From mild to moderate severity symptoms, first a 
 H2-receptor antagonist (H2RA) therapy is recommended. This can be 
used as a maintenance option in patients without erosive disease if pa-
tients experience heartburn relief (conditional recommendation, mod-
erate level of evidence).  
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If H2RA therapy is not sufficient and the patient has moderate to severe 
symptoms: 
 An 8-week course of PPIs is the therapy of choice for symptom relief 
and healing of erosive esophagitis. There are no major differences in 
efficacy between the different PPIs (strong recommendation, high lev-
el of evidence). 
 PPI therapy should be initiated at once a day dosing before the first 
meal of the day (strong recommendation, moderate level of evidence).  
 For patients with partial response to once daily PPI therapy, tailored 
therapy with adjustment of dose timing and/or twice daily dosing 
should be considered (strong recommendation, low level of evidence). 
Switching to a different PPI may provide additional symptom relief 
(conditional recommendation, low level evidence). 
 Maintenance of PPI therapy should be administered for GERD pa-
tients who continue to have symptoms after PPI is discontinued and 
in patients with complications including erosive esophagitis and Bar-
rett’s esophagus (strong recommendation, moderate level of evidence). 
For patients who require long-term PPI therapy, it should be admin-
istered in the lowest effective dose, including on demand or intermit-
tent therapy (conditional recommendation, low level of evidence). 
 Non-responders to PPI should be referred for evaluation (conditional 
recommendation, low level of evidence). 
Recommendations number 1-2 can only prevent approximately 20% of pa-
tients from a relapse. The relapse rate after discontinuation of the medication 
accounts for 90% [20].  
For patients with refractory GERD, there is no standardized management 
algorithm. The primary goal of treatment is symptom reduction and eventual 
elimination [15]. 
The management of GERD is displayed in the following figure.  
 
PPI: proton pump inhibitor, H2RA: H2-receptor antagonist, GERD: gastroesophageal reflux disease 
Figure 4-1: Algorithmic approach to medical treatment of GERD [12] 
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Life-style modifications and medical treatment are the first-line therapy op-
tions. Surgical management is the second-line treatment. Before considering 
surgery, objective documentation of the gastroesophageal reflux is mandatory. 
Surgical therapy should be considered in patients who: 
 have failed medical management (inadequate symptom control, severe 
regurgitation not controlled with acid suppression, or medication side 
effects); 
 opt for surgery despite successful medical management (due to quality 
of life considerations, lifelong need for medication intake, expense of 
medications, etc.); 
 have complications of GERD  
(e.g. Barrett’s esophagus, peptic stricture); 
 have extra-esophageal manifestations  
(asthma, hoarseness, cough, chest pain, aspiration). 
The coexistence of Barrett’s esophagus with gastroesophageal reflux symptoms 
is considered a clear indication for antireflux surgery. Surgical intervention 
for asymptomatic Barrett’s esophagus is more controversial, however [1, 13]. 
It is important to note that there is no one best operation for all patients. Fac-
tors such as the degree of esophageal shortening, local expertise with laparo-
scopic techniques, prior operations and esophageal motility disorders, and the 
size of hiatal hernia can influence the choice of operation [13]. 
Choice of surgical procedure is displayed in the following figure: 
 
TLESR: Transient lower esophageal sphincter relaxation; TIF: trans-oral incisionless fundoplication,  
LES: lower esophageal sphincter 
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Target population 
A0007 – What is the target population in this assessment? 
The target population in this assessment is adult patients with moderate to 
severe GERD, who are considered for surgical treatment due to incomplete 
symptom control despite maximum medication treatment or severe compli-
cations associated with PPI therapy.  
A0023 – How many people belong to the target population?  
The prevalence of GERD is around 15% [1, 18] and the incidence is increas-
ing. It is the most common upper gastrointestinal disease in the Western coun-
tries, with 10-20% of the population experiencing weekly symptoms [14]. 25-
42% of patients are refractory to a once-daily PPI, of which 25% would re-
spond to an increase in PPI dosing to twice daily. However, 42% of GERD 
patients are dissatisfied with their PPI treatment outcomes [15]. 
In 2014, the Code LM030 (open fundoplication/hiatusplasty) was reimbursed 
98 times, the LM040 (laparoscopic fundoplication/hiatusplasty) was refund-
ed 1723 times.  
A0011 – What is the expected utilisation of MSAD?  
The expected annual utilisation of MSAD, based on the previous years’ ex-
perience, would be 100 interventions per year in Austria.  
 
Prävalenz 15 % 
25-42 % der 
PatientInnen sind einmal 
pro Tag PPI-refraktär 




 LBI-HTA | 2016 31 
5 Clinical effectiveness 
Research questions 
Clinical Effectiveness 
Element ID Research question 
D0005 How does MSAD affect heartburn, regurgitation, and extraesophageal symptoms? 
D0006 How does MSAD affect the continuation with PPI therapy? 
D0011 What is the effect of MSAD on dysphagia and bloating? 
D0016 How does MSAD affect activities of daily living? 
D0013 What is the effect of MSAD on disease-specific quality of life? 




The following outcomes were defined as crucial for patients: 
 GERD HRQL score 
Further outcomes considered were: 
 Heartburn 
 Daily regurgitation 
 Dysphagia 
 Excessive bloating 
 Extra-esophageal symptoms 
 Discontinuation with or reduction of PPIs 
GERD health-related quality of life score:  
Since, according to the traditional concept, GERD is a degenerative disease, 
the ultimate aim of MSAD is to stop the process of degeneration by taking 
on the function of the esophageal sphincter and thus to improve the quality 
of life. Hence, GERD health-related quality of life score is considered a rele-
vant primary outcome as the score represents a summation of patient-relevant 
items. It measures changes in typical GERD symptoms in response to a sur-
gical or medical treatment and so includes questions about heartburn, diffi-
culty swallowing, bloating, and medication intake. The best possible score is 
0 (i.e., asymptomatic in each item), and the worst possible scores is 50 (inca-
pacitated in each item). It also reflects of patient satisfaction as it includes a 
question worded “How satisfied are you with your present condition?” This 
item is a numerical score and it is not reflected in the total GERD-HRQL 
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5.2 Included studies 
For assessing clinical effectiveness of MSAD on GERD, only one study ful-
filled the inclusion criteria [22]. Study characteristics and results of included 
studies are displayed in Table A-1 and in the evidence profile in Table 7-1. 
Study characteristics: 
It was a prospective registry-based case control study done in the setting of 
real clinical practice in 22 medical centres in four countries. The control group 
included patients undergoing LF. The study was sponsored by the manufac-
turer Torax Medical Inc. Overall, 249 patients completed 1 year follow-up of 
which 202 underwent the MSAD intervention and 77 were women and 125 
men [22]. Median operative time was not stated. 
Patient characteristics: 
Important to note are the differences in inclusion criteria between MSAD and 
LF patients within the study. LF patients were in a more severe stage of GERD 
in terms of hiatal hernias sized >3 cm with 45.7% LF patients compared to 
only 1.6% MSAD patients. There were more patients with Barrett’s esophagus 
in the LF group with 19.1% over 1.0% in MSAD and with esophagitis grade C 
and D, 8.5% in LF compared to 1% in MSAD. The mean BMI score, the num-
ber of years on PPIs as well as the number of years with GERD were similar. 
These above mentioned differences are significant because they are signs of 





No data on mortality were reported. 
D0005 – How does MSAD affect heartburn, regurgitation, 
extraesophageal symptoms, and frequency of esophageal symptoms? 
In MSAD patients, the registry indicated an improvement in heartburn from 
baseline 30.8% to 3.5% at one year follow-up, whereas in the LF group, there 
was an improvement of 40% to 8.5% [22].  
In the registry, regurgitation dropped from 60% to 13% in LF patients vs., 
58.2% to 3.1% in the MSAD group [22].  
In terms of frequency of extraesophageal symptoms, the registry study report-
ed improvement of 63.9% to 22.3% in the MSAD group vs. 53.3% to 17.4% 
in the LF group [22]. 
 
D0006 – How does MSAD affect the continuation with PPI therapy? 
In the registry study, 81.8% of patients with MSAD discontinued PPI therapy 
compared to 63% of patients undergoing LF [22]. 
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D0011 – What is the effect of MSAD on dysphagia  
and excessive bloating? 
The registry study only included data on post-operative excessive bloating 
with 10% in MSAD patients and 31.9% in LF patients, dysphagia was not 
reported on [22].  
D0013 – What is the effect of MSAD on disease-specific quality of life? 
Comparing MSAD to LF, MSAD patients improved from 20 to 3 points in 
GERD HRQL and LF patients improved from 23 to 3.5 [22]. 
D0017 – Was the use of MSAD worthwhile? 
Comparing MSAD to LF, 91.8% of MSAD patient were satisfied at follow-
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6 Safety 
Safety 
Element ID Research question 
C0008 How safe is MSAD in comparison to LF? 
C0004 How does the frequency or severity of harms change over time or in different settings? 
C0005 What are the susceptible patient groups that are more likely to be harmed through  
the use of the technology? 
C0007 Are MSAD and LF associated with user-dependent harms? 




The following outcomes were defined as crucial to derive a recommendation: 
 Dysphagia 
 Excessive bloating 
 Device removal 
 Device migration 
 Device erosion 
 Device malfunction 
 Re-hospitalisation  
 Re-operation 
 Intraoperative complications 
Further outcomes considered were: 
 Inability to belch or vomit 
 Other AEs 
In order to assess the relative effectiveness of an intervention, balancing harms 
against benefits is crucial. Procedure related AE and serious AEs are of spe-
cial importance and were thus considered as crucial for assessing the safety 
profile of MSAD. 
Due to the fact that MSAD is an implant foreign to the body, it carries with 
itself both safety benefits and concerns. On the one hand, the procedure is 
reversible, yet on the other, the way the body accepts the implant remains to 
be a safety concern. To monitor the process of acceptance of the implant, in-
traoperative complications (time period during operation), post-operative (any 
period after operation) dysphagia (difficulty with swallowing) and device re-
moval, device migration, malfunction or erosion, re-hospitalisation and re-op-
eration were chosen to be the crucial outcomes. Dysphagia was chosen to be 
the crucial outcome because it is the most common adverse event in fundopli-
cation. Device removal is taken to be an indicator of both device failure as 
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6.2 Included Studies 
For assessing safety of MSAD on GERD, six studies passed the inclusion cri-
teria [4, 22-26]. The studies comprise five prospective case series [4, 23-26] and 
one prospective registry with control group [22]. Study characteristics and re-
sults of included studies are displayed in Table A-1, Table A-2 and in the evi-
dence profile in Table 7-1. 
Study characteristics: 
Overall, 356 patients were reported on in the prospective case series that were 
all sponsored by the manufacturer Torax Medical Inc., of which 144 were 
women and 212 were men. The prospective registry with control group in-
cluded 249 patients, of which 202 underwent the MSAD intervention where 
77 were women and 125 men [22]. However, because of a high probability of 
double reporting [4, 22], the total number of patients that have undergone the 
MSAD surgery ranges between 558 and 435. Clinical follow-up time ranged 
from one month to five years, with only two studies with longer mean follow-
up of three and five years, respectively [4, 23]. Loss to follow-up ranged from 
0-15 patients. Median operative time ranged from 23-60 minutes in the pro-
spective case series, unreported in the registry. 
Patient characteristics: 
Inclusion criteria showed some heterogeneity in terms of age, length of GERD 
symptoms, PPI resistance and responsiveness, and pathological reflux. The 
age of inclusion varied from 18-86 [26] to 20-68 [25] with one study [22] not 
reporting on the age range. Inclusion criteria in three studies required GERD 
symptoms to last for at least 6 months [4, 23, 24], while the remaining stud-
ies did not state the required length of confirmed GERD. Data on median 
number of years with GERD was stated in four studies [4, 22, 23, 25] and 
ranged from 4-10 years, but was left unreported in the remaining two stud-
ies. PPI resistant GERD was a criterion for inclusion in two studies [23, 24] 
and PPI responsive GERD was an inclusion criterion in three [4, 22, 24]. Data 
on median number of years of PPI use was again stated in four studies [4, 22, 
23, 25] and ranged from 1-6.3 years, and was left unreported in the remain-
ing two studies. Furthermore, confirmed pathological reflux was a require-
ment in two studies [4, 23]. 
Exclusion criteria were more homogenous with all studies restricting the study 
population to patients without Barrett’s esophagus, even though two studies 
ended up operating on two and three patients with Barrett’s esophagus re-
spectively [4, 26]. All but one excluded patients with motility disorder [26] 
and hiatal hernias sized >3 cm [22]; it was the prospective registry study 
which included 1.6% of MSAD and 45.7% of LF patients with hiatal hernias 
>3 cm. Also, regardless of the exclusion criteria, two patients from Bonavina 
2013 had a hiatal hernia >3 cm [4]. There was a set limit of 35 points in the 
BMI score in two studies [4, 23], while median BMI ranged from 24-28 with 
one study not reporting on this data [24]. Further heterogeneity in exclusion 
criteria was with reference to esophagitis, where two studies formally exclud-
ed patients with esophagitis grade B, C and D [4, 26], yet in practice, one of 
them included six esophagitis grade B patients [4]. Compared to the rest of 
the studies, only those patients who were diagnosed with esophagitis grade C 
and D were excluded, yet again, in practice, the prospective registry study in-
cluded in both groups, 1% of MSAD and 8.5% of LF, the patients with esoph-
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agitis grade C and D [22]. Confirmed allergy to metals was an exclusion cri-
teria in three studies [4, 23] and further two studies had an extra exclusion 





C0008 – How safe is MSAD in comparison to LF? 
Only the registry study allows for comparison of the dysphagia, excessive 
bloating, inability to belch or vomit, intraoperative complications, re-opera-
tion rate, and re-hospitalization rate between the MSAD and LF groups.  
The registry study reported that post-operative excessive bloating was 10% 
in MSAD patients, compared to 31.9% in LF. No significant difference was 
observed between the two groups regarding the intraoperative complication 
rates (1.49% in MSAD vs. 2.13% in LF). 1.6% of MSAD patients experienced 
the inability to belch compared to 10.1% of LF patients, 8.7% of MSAD pa-
tients experienced the inability to vomit compared to 56.6% of LF patients. 
7% of MSAD patients and 10.6% of LF patients experienced dysphagia at 1 
year follow-up. 4% of MSAD patients were re-operated due to device remov-
al, compared to 6.4% of patients in the LF group that were re-operated due 
to persistent GERD and herniation of the fundic wrap [22]. Hospital read-
mission rate was 5.4% for MSAD patients compared to 4.3% for LF patients 
[22]. 
Device removal, erosion, migration, and malfunctioning were considered in 
the case series and the registry study, because the effects directly attributable 
to the device can be analyzed without comparator group as well. Device re-
moval was reported in five studies. Two studies with short-term (up to 1 year) 
follow-up indicated 0% of device removal rate [25, 26], compared to three 
long-term studies (1 to 5 year) that indicated the device removal rate of 4% 
at one year follow-up [22], 3% at three year follow-up[4], and 7% at five year 
follow-up [23]. Device erosion and migration was reported in three [4, 23, 26] 
resp. two studies [4, 23], but occurred in none. Device malfunctioning/unlock-
ing was reported only in one study, but did not occur [23].  
C0004 – How does the frequency or severity  
of harms change over time or in different settings? 
With the new generation of the device, the safety profile does not vary. The 
main difference between the device generations is in their MRI compliance. 
The first generation is up to 0.7 tesla, whereas the second is up to 1.5 tesla 
MRI compatible. Other minor differences include securing the ends of the 
device; in the first generation a Ti-Knot Replacement System (LSI Solutions) 
was used, whereas in the second generation a clasp was used instead of a su-
ture [4]. Additionally, sizing of the esophagus in the first generation used a 
color-coded sizing device of connected beads, whereas in the second genera-
tion, a laparoscopic sizing tool was introduced [4]. 
There is no evidence that harms increase or decrease in different organiza-
tional settings. 
nur die Registerstudie 
ermöglicht einen  
Vergleich bei: 
Dysphagie  
Übermäßigen Blähungen  
Unfähigkeit zu Rülpsen 






Erosion, Migration und 
Fehlfunktionen wurden 
in den Fallserien sowie 
der Registerstudie 
berücksichtigt 
Sicherheit bei  
MRI Untersuchungen: 
1.Generation:  
bis zu 0.7 tesla 
2.Generation:  
bis zu 1.5 tesla 
Magnetic sphincter augmentation device (MSAD) in patients with gastroesophageal reflux disease (GERD) 
38 LBI-HTA | 2016 
C0005 – What are the susceptible patient groups  
that are more likely to be harmed through the use of the technology? 
Patients susceptible to be harmed through the use of the technology are those 
whose health condition already required a solution in the shape of a magnet-
ic implant, such as implantable cardioverter-defibrillators. Also, patients who 
need to undergo MRI are at risk as, in the Bonavina 2013 study, a total of 8 
patients reported undergoing MRI out of which 2 patients reported discom-
fort during the MRI and chest X-Ray for both of these patients showed the 
device in a more open geometry [4]. 
C0007 – Are MSAD and LF associated with user-dependent harms? 
Malfunction of the device due to deficient user training is possible as it is 
crucial for patients to eat an unrestricted diet as soon as tolerated. The pro-
cess of swallowing a solid bolus of food contributes to the expansion of the 
device or actuating of the beads during healing [4]. 
The learning curve for placement of the MSAD was not steep [27]. Risks re-
lated to administration of the device stem from the surgeon’s ability to min-
imize the amount of dissection performed and to carefully locate and dissect 
the posterior vagus nerve [27]. The surgeon needs to avoid reverting back to 
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7 Quality of evidence 
The strength of evidence was rated according to GRADE (Grading of Recom-
mendations Assessment, Development and Evaluation) Schema [28] for each 
endpoint individually. Each study was rated by two independent researchers. 
In case of disagreement a third researcher was involved to solve the difference. 
A more detailed list of criteria applied can be found in the recommendations 
of the GRADE Working Group [28].  
GRADE uses four categories to rank the strength of evidence: 
 High = We are very confident that the true effect lies close  
to that of the estimate of the effect;  
 Moderate = We are moderately confident in the effect estimate:  
the true effect is likely to be close to the estimate of the effect, but 
there is a possibility that it is substantially different;  
 Low = Our confidence in the effect estimate is limited: the true effect 
may be substantially different from the estimate of the effect;  
 Very low = Evidence either is unavailable or does not permit  
a conclusion. 
The ranking according to the GRADE scheme for the research question can 
be found in Table 7-1.  
Overall, the strength of evidence for the effectiveness and safety of MSAD in 
comparison to LF is very low to moderate. 
 












































Table 7-1: Evidence profile: efficacy and safety of MSAD in GERD patients 
No of studies/ 
patients Study Design Estimate of effect 
Study 






Median GERD HRQL score (pre-op./last follow-up) I vs. C 
1/249 Prospective registry with control group 20/3 vs. 23/3.5 (p=0.177) 0 NA 0 0 Moderate 
Safety 
Overall complication rate, % I vs. C 
1/249 Prospective registry with control group NA NA NA NA NA NA 
Intraoperative complications, % I vs. C 
1/249 Prospective registry with control group 1.49 vs. 2.13 (p=1.00) 0 NA 0 0 Moderate 
Dysphagia, % I vs. C 
1/249 Prospective registry with control group 7 vs. 10.6 (p=0.373) 0 NA 0 0 Moderate 
Device removal, % 
5/336 Prospective case series + prospective registry  
with control group 
0-7 -1 -1 0 -12 Very low 
Nomenclature for GRADE table:  
Limitations: 0: no limitations or no serious limitations; -1: serious limitations  
Inconsistency: NA: Not applicable (only one trial); 0: no important inconsistency; -1: important inconsistency  
Indirectness: 0: direct, no uncertainty, -1: some uncertainty, -2 major uncertainty  
Other modifying factors: publication bias likely (-1), imprecise data (-1), strong or very strong association (+1 or +2), dose-response gradient (+1), Plausible confounding (+1)  
Legend: I: intervention; C: control; GERD HRQL: gastroesophageal reflux disease health-related quality of life  
 
 
                                                             
2 Out of the total of 5 prospective case series included in the analysis, only 4 are reporting on this outcome. 
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8 Discussion 
Since MSAD is a new intervention, there is scarce data on the clinical effec-
tiveness and safety of the device. MSAD received the FDA approval based on 
a 2 year follow-up data in 2012 with the required 5 year follow-up data avail-
able in 2015 included in this assessment [11]. For the purposes of the assess-
ment, we have restricted our analysis to prospective studies as the best avail-
able evidence, of which we could identify six. Lacking randomized controlled 
trials, there is an absence of robust clinical data comparing MSAD with the 
best available alternative, LF. 
In terms of clinical effectiveness, only one study fulfilled the inclusion crite-
ria [22], which, with regards to patient characteristics as outlined in the clini-
cal effectiveness section, included such different patient groups for each inter-
vention that the comparative value of the study as such remains undermined.  
When comparing the registry study to the case series, which did not pass the 
inclusion criteria for clinical effectiveness, heterogeneity in results can be ob-
served with regards to heartburn, where two studies reported a significant re-
duction in the percentage of patients experiencing heartburn within a short-
term follow-up time of 1 month [25], and long-term follow-up time of 5 years 
[23]. The registry study indicated a less significant decline both in MSAD and 
LF groups with very similar results, within the follow-up of 1 year [22]. Im-
portant to note is that the five year study showed recurrence of the disease 
[23], where the baseline heartburn of 89% decreased to 3.2% at one year fol-
low-up, but progressively grew to 5.6% at two year follow-up, 8% at three year 
follow-up, 9.3% at four year follow-up, and 11.9% at five year follow-up. 
All the rest of the reported outcomes suggest homogeneity between the regis-
try and the case series. Important to note is that the case series data not only 
match the clinical effectiveness data of MSAD, but, drawing upon the registry 
data, to a large extent, they match the clinical effectiveness data of LF as well. 
The homogenous outcomes include: regurgitation, extraesophageal symptoms, 
discontinuation of PPI therapy, GERD HRQL, and overall satisfaction. All 
of these outcomes have shown slight to significant improvement both in the 
single-arm studies and in the registry study. The two groups in the registry 
study had similar results in all but one outcome, 81.8% of MSAD patients dis-
continued PPI therapy compared to 63% of patients undergoing LF [22]. In 
the registry, dysphagia was not reported both pre- and post-operatively, but it 
remains important to highlight that the data in the case series varied greatly, 
whereby studies with short-term follow-up [24, 25] indicated a significant wors-
ening in dysphagia and studies with long-term follow-up indicated improve-
ment or slight worsening [4, 23]. 
Device-related safety data on MSAD based on all the six prospective studies 
included indicate relative safety of the device; however, based upon the reg-
istry study, the post-operative side-effects compared to LF cannot be directly 
assessed due to the different severity of the disease in the two patient groups. 
Nonetheless, the major advantages of the MSA procedure known to date are 
that it is less invasive and reversible, its implantation is associated with a 
shorter learning curve for the surgeon, it requires a shorter hospital stay, and 
allows a faster return to normal diet. One question mark remains with long-
term safety of MSAD due to the device removal data, which seem to indicate 
a pattern of the longer the follow-up, the more device removals.  
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Overall, the strength of evidence is moderate for efficacy and very low to mod-
erate for safety outcomes. The case series were concluded to have a high risk of 
bias, the registry study being the only one with a low risk of bias. Three stud-
ies were conducted in multiple centres where multiple-reporting was proba-
ble. Bonavina 2013 [4] was reporting on the same cohort as studies that we ex-
cluded for that reason [27, 29-31]. The registry study [22] was with high prob-
ability including patients from Bonavina 2013 [4] and Schwameis 2014 [25]. 
The methodological limitations include: unclear selection process [23, 26], 
non-consecutive recruitment of study participants [4, 23], unclear if entering 
the study at a similar point in the disease [22, 24, 26] or clearly not fulfilling 
this criteria [4, 23, 25], non-reporting about competing interests or sources of 
support for the study [24-26], and a high loss to follow-up [23, 24]. All six 
studies were sponsored by the manufacturer Torax Medical Inc., and all of the 
effectiveness outcomes were patient reported, hence subject to high risk of bias.  
Uncertainties about the applicability of evidence stem from the ambiguity of 
alternatives. On the one hand, LF is presented as an alternative, yet on the 
other hand, MSAD claims to fill the “therapeutic gap between patients who 
are dissatisfied with PPI treatment and those who are reluctant to undergo 
Nissen fundoplication” [31]. The target population of MSAD seems to be less 
severe patients not indicated for fundoplication, which changes the cut-off 
point of a surgical intervention to the less diseased. In the light of this ambi-
guity, ethicality of an RCT between MSAD and LF is put into question. Hence, 
under these circumstances, a sham RCT is needed to confirm the efficacy of 
MSAD.  
There are some other emerging technologies that are willing to fill the above 
mentioned therapeutic gap. These can be categorized into 3 groups:  
1. radiofrequency ablation of the LES (Stretta System)  
2. trans-oral incisionless fundoplication (TIF), i.e. suturing  
of the gastroesophageal junction 
3. lower esophageal sphincter electrical stimulation therapy (LES-EST) 
[8, 15, 32]. 
The first two alternatives provide a non-surgical approach, while the LES-EST 
is a non-ablative and easily reversible minimally invasive surgical interven-
tion, like MSA. The TIF seems to be safe and effective with 79-80% response 
rates, although with disappointing 2-year follow-up results, and it is recom-
mended only for patients with hiatal hernia <2 cm. The Stretta System is re-
commended by SAGES for non-complicated GERD and it is the only one that 
has undergone rigorous evaluation with randomized trials with excellent re-
sults. The safety profile of LES-EST is also very good so far, effectiveness data 
are comparable to MSA and it is indicated for the same patient group [8, 15, 
32]. 
Untreated chronic reflux might lead to secondary diseases, such as erosive 
esophagitis, oesophageal stricture, Barrett’s esophagus, or even oesophageal 
cancer, therefore the effect of MSAD on these outcomes also needs to be ana-
lysed. In case MSAD fulfils the mentioned therapeutic gap, it can be consid-
ered as the first line surgical treatment for prevention of the oesophageal can-
cer and, on the long run, as an option bringing savings to the health care sys-
tem when contrasted to the costly PPI therapy. Furthermore, long-term PPI 
therapy can have serious side-effects, such as decreased calcium absorption, 
osteoporosis, community acquired pneumonia, Clostridium difficile infection, 
small intestinal bacterial overgrowth, vitamin B12 deficiency, and drug inter-
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Further issues with MSAD are related to the change in the cut-off point of a 
surgical intervention in case MSAD fulfils the mentioned therapeutic gap. 
In the absence of clear severity scores supporting staging of well-defined in-
dications, there is a potential risk of MSAD facilitating unhealthy behaviour 
instead of a change in the patient’s dietary habits, particularly in the obese.  
Studies with longer follow-up, involving larger number of implanted patients 
with various patient characteristics (size of hiatal hernia and severity of esoph-
agitis) should be conducted to help determine the exact patient group that 
would benefit most from the intervention.  
 





 LBI-HTA | 2016 45 
9 Recommendation 
In Table 9-1 the scheme for recommendations is displayed and the according 
choice is highlighted. 
Table 9-1: Evidence based recommendations 
 The inclusion in the catalogue of benefits is recommended.  
 The inclusion in the catalogue of benefits is recommended with restrictions. 
X The inclusion in the catalogue of benefits is currently not recommended. 
 The inclusion in the catalogue of benefits is not recommended. 
 
Reasoning: 
The current evidence is not sufficient to prove that the assessed technology, 
MSAD, is at least equally effective and as safe as the comparator LF. Com-
parative data on the two procedures are available from a single registry study 
where the LF group was in a more severe stage of the disease and neverthe-
less achieved a similar improvement in GERD related quality of life as the 
MSAD group. Concerning safety, the re-operation and hospital re-admission 
rates were similar; the difference in other complications like dysphagia was 
statistically not significant. Significant difference is only shown in the inabil-
ity to belch or vomit, and in excessive bloating. However the confidence in 
these comparative results is limited, due to the observational study design, 
the limited number of patients, and the differences in the patient character-
istics in the two study groups. Results from high-quality sham control studies 
or RCTs comparing MSAD and LF will potentially influence the effect esti-
mate considerably.  
Currently, there are no registered ongoing or planned controlled trials com-
paring the LINX device with LF (Table A-5 in the Appendix). Additionally, 
one ongoing clinical trial is comparing the LINX device with Omeprazole 
(PPI); two trials do not have any comparators. One of them is assessing the 
LINX device in a new patient group (GERD patients who previously had lap-
aroscopic sleeve gastrectomy for obesity) and the other one is a 5-year post-
approval study of LINX.  
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Evidence tables of individual studies included for clinical effectiveness and safety 
Table A-1: MSAD: Results from observational studies included for safety  
 Bonavina 2013 [4] Schwameis 2014 [25] Smith 2014 [26] Reynolds 2014 [24] Ganz 2015 [23] 
Country Italy Austria United States United States United States, Netherlands 
Sponsor Torax Medical Inc. Torax Medical Inc. Torax Medical Inc. Torax Medical Inc. Torax Medical Inc. 










Intervention  LP MSAD LP MSAD LP MSAD LP MSAD LP MSAD 
Number of pts  1003 23 66 67 100 
Inclusion criteria Pts>18yrs, GERD ≥6mos,  
PPI resistant reflux,  
pathologic reflux 
At least partial response to 
PPIs, PPI resistant GERD 
GERD, acceptable esophageal 
motility, clinical improvement on 
antisecretory medication with 
incomplete symptom control, 
medication intolerance,  
or side effects 
Pts>18yrs, GERD> 6mos Pts>18yrs <75yrs,  
GERD ≥6mos, at least 
partial response to PPIs, 
pathologic reflux 
Exclusion criteria Hiatal hernia >3 cm, 
esophagitis grade B+, BMI >35, 
Barrett’s esophagus, motility 
disorder, gross esophageal 
anatomic abnormalities, 
allergy to the device’s 
material (titanium, stainless 
steel, nickel, or ferrous 
materials) 




grade C or D, allergy to the 
device’s material (titanium, 
stainless steel, nickel, 
ferrous materials) 
Hiatal hernia>3 cm, advanced 
GERD, Barrett’s esophagus, 
esophagitis grade B+ 
Hiatal hernia >3 cm, 
motility disorder, 
esophagitis grade C or D, 
Barrett’s esophagus, gross 
esophageal anatomic 
abnormalities, allergy to 
the device’s material 
(titanium, stainless steel, 
nickel, ferrous materials 
Hiatal hernia ≥3 cm, 




Baseline patient characteristics      
Median age, yrs  44.5 (range 23-77) 43 (range 20-68) 53.7 (range 18-86) 53 (range 19-81) 53 (range 18-75) 
Sex, female vs. male (26 vs. 74) 12 vs. 11 38 vs. 28 20 vs. 47 48 vs. 52 
                                                             
3 Patients 1 through 30 (30%) underwent the implantation procedure between March 2007 and May 2008 as part of a multi-centre (US, IT) pilot study of 41 patients (Bonavina 2008; 
treated with 1st generation LINX). Patients 31 through 100 (70%) underwent the implantation procedure between December 2009 and February 2012 as part of a registry (treated 










































 Bonavina 2013 [4] Schwameis 2014 [25] Smith 2014 [26] Reynolds 2014 [24] Ganz 2015 [23] 
BMI  Median 24 (range 17.3-33.0) Median 26 (range 20-32) Mean 26 (range 17.6-34.1) NA Median 28 (range 20-35) 
Hiatal hernia ≤=3 cm, % 984 1005 676 NA NA 
Median yrs of PPI use 4 1 (range 0-20) NA NA 5 
Median yrs with GERD 5.5 4 (range 1-20) NA NA 10 (range 1-40) 
Barrett’s esophagus, n 2 NA 3 NA NA 
Esophagitis, % 
Grade A and B 
















Follow-up time 3 yrs (range 378 days-6 yrs) 1 mo 5.8 mos (range 1-18.6 mos) 5 mos (range 3-14 mos) 5 yrs 
Loss to follow-up, n 57 0 1 15 15 
Median operative time, min  47 23 NA 60 368 
Outcomes 
Efficacy 
Median GERD HRQL score 
(pre-op./last follow-up) 
24 off PPIs/2 29/4 (p<0.001) 26/6 NA/4 (range 0-26) 27/4 (p<0.001) 
Heartburn, %  
(pre-op./last follow-up) 
NA 95.7/22 (p<0.001) NA NA 89/11.9 (p<0.001) 
Daily regurgitation, %  
(pre-op./last follow-up) 
72/2 65/57 (p>0.1) NA NA/44.2 57/1.2 (p<0.001) 
Dysphagia, %  
(pre-op./last follow-up) 
8/0 48/70 (p>0.1) NA 0.02/82.79 5/6 (p=0.739) 
Excessive bloating, %  
(pre-op./last follow-up) 
48/2 70/30 (p=0.006) NA NA 52/8.3 (p<0.001) 
                                                             
4 Including the 21 patients that had no hiatal hernia. 77 patients had ≤3 cm hiatal hernia.  
5 Including the patients that had no hernia. The mean hiatal hernia size was 1.34 cm (range 0-2 cm). 
6 No information on the size of the hernia.  
7 Out of the 41 patients of the pilot study (Bonavina 2008) 11 patients were lost to follow-up. Out of the cohort of 100 patients (30 patients from the pilot study and 70 registry patients) 
5 were lost to follow-up. 
8 This data comes from an earlier report of the same study of Ganz et al. 2013, Esophageal Sphincter Device for Gastroesophageal Reflux Disease. 
9 55.8 described it as mild, characterized by a feeling of food sticking or occasional regurgitation. A total of 44.2 described their dysphagia as severe as characterized by daily  
















 Bonavina 2013 [4] Schwameis 2014 [25] Smith 2014 [26] Reynolds 2014 [24] Ganz 2015 [23] 
Extra-esophageal symptoms 
(asthma, chronic cough, 
laryngitis), %  
(pre-op./last follow-up) 
52/16 57/17 (p=0.039) NA NA NA 
Discontinuation of 
medication (PPIs), % 
85 71.410 83 76.9 84.711 (CI 95%, 81-95) 
DeMeester pH score  
(pre-op./last follow-up) 
Median 30.1/11.2 NA Mean 32.3 (range 1.4-67)/NA NA Median 36.6  
(range 16.3-83.8)5/NA 
Hospital discharge, % 96 (within 48 hrs) 52 (within 24 hrs),  
82.6 (within 48 hrs) 
25 (within 24 hrs) 51 (within 12 hrs),  
100 (within 36 hrs) 
NA 
Patient satisfaction, %  
(pre-op./last follow-up) 
5/87 0/74 NA/9212 NA 5/92.913 (p<0.001) 
Safety 
ADEs, SADEs %      
Inability to belch 1 0 NA NA NA 
Inability to vomit 1 0 NA NA NA 
Other non-serious ADEs 4 mild odynophagia,  
3 increased belching 
NA NA14 0.67 dehydration,  
2 urinary retentions 
NA 
Dysphagia 2 0.23 2.64 5.36 NA 
Intraoperative 
complications 
0 0 0 0 NA 
Device erosion 0 NA 0 NA 0 
Device migration 0 NA NA NA 0 
Device malfunction/unlocking NA NA NA NA 0 
Device removal 3 0 0 NA 7 
 
                                                             
10 2 patients (9.5%) were already off medication at baseline due to severe side-effects from PPIs. 2 further patients were able to halve their daily PPI dosage. 
11 At 5 years, 75.3% of patients reported complete cessation of PPIs, and 9.4% reported PPI use only as needed. 
12 Patients who were satisfied or neutral about the intervention. 
13 Defined through patient dissatisfaction where at baseline, 95% were dissatisfied and at 5 years, 7.1% were dissatisfied. 
14 A total of 8.58% of patients underwent 11.22% of contrast swallows, 4.62% of dilatations, 7.91% of EGDs (esophagogastroduodenoscopy), 3.3% of pH testing and 0.66% of motility 
test mainly for diagnosis. Dilatations were done in 2.64% of patients for dysphagia. 
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Table A-2: MSAD: Results from prospective registry with control group included for effectiveness 
 Riegler 2015 [22] 
Country Austria, Germany, Italy, United Kingdom 
Sponsor Torax Medical Inc. 
Study design Multi-centre prospective registry with control group 
(NCT01624506) 
Intervention (I) LP MSAD 
Comparator (C) LF 
Number of pts (I vs. C) 249 (202 vs. 47) 
Inclusion criteria Advanced GERD with hiatal hernia >3 cm, Barrett’s 
esophagus, motility disorder, or esophagitis grade C or D 
Moderate GERD with abnormal esophageal pH, reflux 
symptoms despite PPI use 
Exclusion criteria Known conditions that make it unlikely to complete  
a 3-year follow-up 
Baseline patient characteristics (I vs. C)  
Mean age, yrs 46.6 vs. 52.8 (p=0.007) 
Sex, female vs. male  (77 vs. 125) vs. (19 vs. 28) (p=0.866) 
Moderate GERD, % 94 vs. 38.3 
Mean BMI  25.7 vs. 26.1 (p=0.611) 
Hiatal hernia >3 cm, % 1.6 vs. 45.7 (p<0.001) 
Mean yrs of PPI use  6.3 vs. 5.1 (p=0.098) 
Mean yrs with GERD 8.7 vs. 7.3 (p=0.086) 
Barrett’s esophagus, % 1.0 vs. 19.1 (p<0.001) 
Esophagitis, %  
Grade A and Grade B 41.4 vs. 44.7 (p=0.212) 
Grade C and Grade D 1 vs. 8.5 (p=0.212) 
Follow-up time, yrs 1 
Loss to follow-up, n 0 
Median operative time, min  NA 
Outcomes 
Efficacy (I vs. C) 
Median GERD HRQL score (pre-op./last follow-up)15 20/3 vs. 23/3.5 (p=0.177) 
Heartburn waking from sleep, % (pre-op./last follow-up) 30.8/3.5 vs. 40/8.5 (p=0.229) 
Regurgitation, % (pre-op./last follow-up) 58.2/3.1 vs. 60/13 (p=0.014) 
Extra-esophageal symptoms (asthma, chronic cough, 
laryngitis), % (pre-op./last follow-up) 
63.9/22.3 vs. 53.3/17.4 (p=0.552) 
Discontinuation with medication (PPIs),  
% at last follow-up 
81.8 vs. 63 (p=0.009) 
Median DeMeester pH score16 (pre-op./last follow-up) NA 
Hospital discharge, % NA 
Patient satisfaction, % (last follow-up) 91.8 vs 86.7 
                                                             
15 The total GERD-HRQL score represents a summation of 10 items (questions about heartburn, difficulty swallowing, 
bloating, satisfaction and medication take). The best possible score is 0 (i.e., asymptomatic in each item), and the 
worst possible scores is 50 (incapacitated in each item). 
16 Global measure of esophageal acid exposure that quantifies gastroesophageal reflux.  
A DeMeester score > 14.72 indicates reflux. 
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 Riegler 2015 [22] 
Safety 
ADEs, SADEs % at last follow-up (I vs. C)  
Inability to belch 1.6 vs. 10.1 (p=0.007) 
Inability to vomit 8.7 vs. 56.6 (p<0.001) 
Excessive bloating 10 vs 31.9 (p<0.001) 
Dysphagia  7 vs. 10.6 (p=0.373) 
Intraoperative complications  1.49 vs. 2.1317 (p=1.00) 
Reoperation rate  4 vs. 6.418 
Hospital readmission  5.4 vs. 4.3 
Device erosion NA 
Device migration NA 
Device malfunction/unlocking NA 
Device removal 4 
 
                                                             
17 An injury to the pleura in both groups, minor bleeding in 2 patients in the MSDA group.  
18 Reoperations in the MSAD group were performed for device removal due to dysphagia, pain or  










































Risk of bias tables 
Internal validity of the included studies was judged by two independent researchers. In case of disagreement a third researcher was involved to solve the differences. 
A more detailed description of the criteria used to assess the internal validity of the individual study designs can be found in the Internal Manual of the LBI-HTA 
[33] and in the Guidelines of EUnetHTA [34, 35]. 














1. Is the hypothesis/aim/objective of the study stated clearly in the abstract, introduction,  
or methods section? 
Yes Yes Yes Yes Yes Yes 
2. Are the characteristics of the participants included in the study described? Yes Yes Yes Partially reported Yes Yes  
3. Were the cases collected in more than one centre? No No No Yes Yes Yes  
4. Are the eligibility criteria (inclusion and exclusion criteria) for entry into the study explicit  
and appropriate? 
Yes Yes Yes Yes Yes Partially 
reported19 
5. Were participants recruited consecutively? No20 Yes Unclear21 Yes Unclear22 Yes  
6. Did participants enter the study at similar point in the disease? No No Unclear Unclear No Unclear 
7. Was the intervention clearly described in the study? Yes Yes Yes Yes Yes Yes  
8. Were additional interventions (co-interventions) clearly reported in the study? Yes Yes Yes Yes  No Yes  
9. Are the outcome measures clearly defined in the introduction or methods section? Yes Yes Yes Yes Yes Yes  
10. Were relevant outcomes appropriately measured with objective and/or subjective methods? Yes Yes Yes Yes  Yes Yes  
11. Were outcomes measured before and after intervention? Yes Yes Yes No Yes Yes  
12. Were the statistical tests used to assess the relevant outcomes appropriate? Yes Yes No Yes Yes Yes 
13. Was the length of follow-up reported? Yes Yes Yes Yes Yes Yes  
14. Was the loss to follow-up reported? Yes Yes Yes Yes Yes Yes  
                                                             
19 Exclusion criteria is too vague (patients were excluded if they had known conditions that would make it unlikely for them to complete a 3-year follow-up). 
20 Patients 1 through 30 (30%) underwent the implantation procedure as part of a multicenter pilot study of 41 patients (Magnetic Augmentation of the Lower Esophageal Sphincter: 
Results of a Feasibility Clinical Trial, Bonavina et al. 2008). Patients 31 through 100 (70%) underwent the implantation procedure as part of a registry. 
21 150 patients were evaluated for device implant, 68 were implanted. The selection process is not detailed.  
22 From the 257 patients that signed the consent 100 underwent device implant. The 157 who discontinued: 96 eligibility criteria not met, 36 consent withdrawn, 24 discontinuation 





























15. Does the study provide estimates of the random variability in the data analysis of relevant outcomes? No Yes  No No Yes Yes  
16. Are adverse events reported? Yes Yes Yes Yes Yes Yes  
17. Are the conclusions of the study supported by results? Yes Yes Yes No Yes No  
18. Are both competing interest and source of support for the study reported? Yes No No No Yes Yes  




Table A-4: Summary table characterizing the applicability of a body of studies 
Domain Description of applicability of evidence 
Population Study population represents a narrow spectrum of GERD patients as predifined by the manufacturer and hence for the most part, the target population  
does not differ from the enrolled population. The inclusion criteria predominantly do not reflect severe refractory GERD with hiatal hernias >3 cm,  
motility disorders, Barrett’s easophagus or grade C and D esophagitis, but only mild to moderate GERD with incomplete symptom control by PPIs. 
Intervention Insertion of a magnetic sphincter augmentation device (MSAD) through laparoscopic surgery (LINX® Reflux Management System). 
Comparators Standard surgical treatment of GERD: Nissen fundoplication, partial or Toupet fundoplication. However, there is a slight ambiguity as MSAD attempts to 
place itself into the “treatment gap” for which there is no comparator. It aims at patients who have persistant GERD, incomplete symptom control by PPIs, 
but whose condition is not severe enough to undergo any type of invasive fundoplication. 
Outcomes Clinical effectiveness outcomes reported in the registry study are GERD HRQL, heartburn waking from sleep, regurgitation, discontinuation with PPI 
medication, and extra-esophageal symptoms. Follow-up time was 1 yr and hence long-term effectiveness on GERD may not be assessed.Regardless, the 
outcomes measured do present the most important benefits. 
Safety outcomes that are most frequently reported in the six studies considered are post-operative dysphagia, inability to belch or vomit, intraoperative 
complications, device removal, erosion, and migration. Follow-up time ranged from 1 mo to 5 yrs and hence safety profile of MSAD on GERD may be assessed 
even though its comparative safety to LF cannot. The outcomes measured do present the most important health threats associated with the MSAD.  
Setting All of the studies included were either single-centre or multi-centre studies, with clinical centres based in Europe and the United States.  
Clinical settings were not described in all of the studies, but it is likely that all patients received-standard care at university hospitals or transplant centres. 
Thus, it can be assumed that the results reflect a wide spectrum of clinical routines both with regard to patient selection and treatment modalities and, 
therefore, that results are transferable to the Austrian setting. The surgeon’s technical expertise likely determines the risk of local side effects.  











































List of ongoing trials 
Table A-5: List of ongoing trials of LINX® Reflux Management System 
Identifier/Trial name Patient population Intervention Comparison Primary Outcome 
Primary 
completion date Sponsor 
NCT02505945/ 
The CALIBER Study Randomized Controlled 
Trial of LINX Versus Double-Dose Proton Pump 
Inhibitor Therapy for Reflux Disease 
Patients with GERD LINX device Omeprazole % of subjects with resolution of the 
GERD symptom of interest in each 
arm (time frame: 6 mos) 
October 2016 Torax 
Medical Inc. 
NCT01940185/ 
A Post-Approval Study of the LINX® Reflux 
Management System 
Patients with GERD LINX device - Reduction of total GERD-HRQL 
score (time frame: 6 mos, 12 mos, 
and annually to 60 mos ] 
Serious, device-related adverse 
events (time frame: 60 mos) 
September 2019 Torax 
Medical Inc. 
NCT02429830/ 
A Study of Reflux Management With the 
LINX® System for Gastroesophageal Reflux 
Disease After Laparoscopic Sleeve Gastrectomy 
Patients who have 
previously undergone 
laparoscopic sleeve 
gastrectomy (LSG) for 
obesity and have GERD 
LINX device - Change in GERD-HRQL score  
(time frame: 6 mos) 
Number of participants with  
serious complications 
Change in total distal acid exposure 
% of subjects with esophagitis 
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Literature search strategies 
Search strategy for Cochrane 
Search Name: Magnetic Implants for GERD 
Last Saved: 16/12/2015 12:12:38.569 
ID Search 
#1 MeSH descriptor: [Gastroesophageal Reflux] explode all trees 
#2 “gastro*esophageal reflux“ (Word variations have been searched) 
#3 “gastro-esophageal reflux“ (Word variations have been searched) 
#4 GER:ti,ab,kw (Word variations have been searched) 
#5 GERD:ti,ab,kw (Word variations have been searched) 
#6 GORD:ti,ab,kw (Word variations have been searched) 
#7 “esophageal sphincter“ or “oesophageal sphincter“  
#8 #1 or #2 or #3 or #4 or #5 or #6 or #7  
#9 Sphincter Augmentation* (Word variations have been searched) 
#10 MSA:ti,ab,kw (Word variations have been searched) 
#11 MSAD:ti,ab,kw (Word variations have been searched) 
#12 magnetic near (bead* or band* or ring or device*) (Word variations have been searched) 
#13 MeSH descriptor: [Magnets] explode all trees 
#14 MeSH descriptor: [Esophageal Sphincter, Lower] explode all trees 
#15 esophageal sphincter near (device* or ring* or band* or bead*) (Word variations have been searched) 
#16 (implant* or insert*) next (sphincter* or ring* or bead* or band* or device*)  
(Word variations have been searched) 
#17 MeSH descriptor: [Prostheses and Implants] explode all trees 
#18 MeSH descriptor: [Esophageal Sphincter, Lower] explode all trees 
#19 esophageal sphincter* (Word variations have been searched) 
#20 MeSH descriptor: [Esophagogastric Junction] explode all trees 
#21 gastro*esophageal junction* (Word variations have been searched) 
#22 gastro-esophageal junction* (Word variations have been searched) 
#23 esophagogastric junction* (Word variations have been searched) 
#24 esophago-gastric junction* (Word variations have been searched) 
#25 oesophago-gastric junction* (Word variations have been searched) 
#26 oesophagogastric junction* (Word variations have been searched) 
#27 #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26  
#28 #17 and #27  
#29 “reflux management” (Word variations have been searched) 
#30 “antireflux management” (Word variations have been searched) 
#31 “anti-reflux management” (Word variations have been searched) 
#32 LINX (Word variations have been searched) 
#33 #9 or #10 or #11 or #12 or #13 or #14 or #15 #16 or #28 or #29 or #30 or #31 or #32 




Magnetic sphincter augmentation device (MSAD) in patients with gastroesophageal reflux disease (GERD) 
58 LBI-HTA | 2016 
CRD Search Strategy 
1 MeSH DESCRIPTOR Gastroesophageal Reflux EXPLODE ALL TREES 
2 (gastro*esophageal reflux) 
3 (gastro-esophageal reflux) 




8 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 
9 (Magnetic Sphincter Augmentation*) 
10 (MSA) 
11 (MSAD) 
12 (magnetic NEAR (bead* OR band* OR ring OR device*)) 
13 MeSH DESCRIPTOR Magnets EXPLODE ALL TREES 
14 MeSH DESCRIPTOR Esophageal Sphincter, Lower EXPLODE ALL TREES WITH QUALIFIER SU 
15 (esophageal NEAR (device* OR ring* OR band* OR bead*)) 
16 (oesophageal NEAR (device* OR ring* OR band* OR bead*)) 
17 ((implant* OR insert*) NEAR (sphincter* OR ring* OR bead* OR band* OR device*)) 
18 MeSH DESCRIPTOR Prostheses and Implants EXPLODE ALL TREES 
19 MeSH DESCRIPTOR Esophageal Sphincter, Lower EXPLODE ALL TREES 
20 (esophageal sphincter*) 
21 (oesophageal sphincter*) 
22 MeSH DESCRIPTOR Esophagogastric Junction EXPLODE ALL TREES 
23 (gastro*esophageal junction*) 
24 (gastro-esophageal junction*) 
25 (gastro-oesophageal junction*) 
26 (gastro-oesophageal junction*) 
27 (esophagogastric junction*) 
28 (oesophagogastric junction*) 
29 (oesophago-gastric junction*) 
30 (esophago-gastric junction*) 
31 #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28 
32 #18 AND #31 
33 (reflux management) 
34 (antireflux management) 
35 (anti-reflux management) 
36 (LINX) 
37 #10 OR #12 OR #13 OR #16 OR #17 OR #32 OR #33 OR #36 
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Search strategy for Embase 
No.  Query Results  Results Results Date 
#27 ‘gastroesophageal reflux’/exp OR ‘gastroesophageal reflux’ OR ‘gastrooesophageal 
reflux’ OR ‘gastro-esophageal reflux’ OR ‘gastro-oesophageal reflux’ OR ger:ab,ti 
OR gerd:ab,ti OR gord:ab,ti AND (‘magnetic sphincter augmentation’ OR msa:ab,ti 
OR msad:ab,ti OR magnetic NEAR/4 (bead* OR band* OR ring OR device*) OR 
(‘magnet’/exp AND ‘therapy’/lnk) OR ‘anti reflux implant’/exp OR ‘lower esophagus 
sphincter’/exp/dm_su OR ‘esophageal sphincter’ NEAR/7 (device* OR ring* OR 
band* OR bead*) OR ‘oesophageal sphincter’ NEAR/7 (device* OR ring* OR band* 
OR bead*) OR (implant* OR insert*) NEAR/4 (sphincter* OR ring* OR bead* OR 
band* OR device*) OR ‘reflux management’ OR ‘antireflux management’ OR linx) 
AND (‘clinical trial’/de OR ‘clinical trial (topic)’/de OR ‘comparative effectiveness’/de 
OR ‘comparative study’/de OR ‘controlled clinical trial’/de OR ‘controlled study’/de 
OR ‘major clinical study’/de OR ‘multicenter study’/de OR ‘prospective study’/de 
OR ‘randomized controlled trial’/de OR ‘randomized controlled trial (topic)’/de) OR 
(‘gastroesophageal reflux’/exp OR ‘gastroesophageal reflux’ OR ‘gastrooesophageal 
reflux’ OR ‘gastro-esophageal reflux’ OR ‘gastro-oesophageal reflux’ OR ger:ab,ti 
OR gerd:ab,ti OR gord:ab,ti AND (‘magnetic sphincter augmentation’ OR msa:ab,ti 
OR msad:ab,ti OR magnetic NEAR/4 (bead* OR band* OR ring OR device*) OR 
(‘magnet’/exp AND ‘therapy’/lnk) OR ‘anti reflux implant’/exp OR ‘lower esophagus 
sphincter’/exp/dm_su OR ‘esophageal sphincter’ NEAR/7 (device* OR ring* OR 
band* OR bead*) OR ‘oesophageal sphincter’ NEAR/7 (device* OR ring* OR band* 
OR bead*) OR (implant* OR insert*) NEAR/4 (sphincter* OR ring* OR bead* OR 
band* OR device*) OR ‘reflux management’ OR ‘antireflux management’ OR linx) 
AND ([cochrane review]/lim OR [systematic review]/lim OR [controlled clinical 
trial]/lim OR [randomized controlled trial]/lim OR [meta analysis]/lim)) 
104 14 Dec 2015 
#26 ‘gastroesophageal reflux’/exp OR ‘gastroesophageal reflux’ OR ‘gastrooesophageal 
reflux’ OR ‘gastro-esophageal reflux’ OR ‘gastro-oesophageal reflux’ OR ger:ab,ti 
OR gerd:ab,ti OR gord:ab,ti AND (‘magnetic sphincter augmentation’ OR msa:ab,ti 
OR msad:ab,ti OR magnetic NEAR/4 (bead* OR band* OR ring OR device*) OR 
(‘magnet’/exp AND ‘therapy’/lnk) OR ‘anti reflux implant’/exp OR ‘lower esophagus 
sphincter’/exp/dm_su OR ‘esophageal sphincter’ NEAR/7 (device* OR ring* OR 
band* OR bead*) OR ‘oesophageal sphincter’ NEAR/7 (device* OR ring* OR band* 
OR bead*) OR (implant* OR insert*) NEAR/4 (sphincter* OR ring* OR bead* OR 
band* OR device*) OR ‘reflux management’ OR ‘antireflux management’ OR linx) 
AND ([cochrane review]/lim OR [systematic review]/lim OR [controlled clinical 
trial]/lim OR [randomized controlled trial]/lim OR [meta analysis]/lim) 
15 14 Dec 2015 
#25 ‘gastroesophageal reflux’/exp OR ‘gastroesophageal reflux’ OR ‘gastrooesophageal 
reflux’ OR ‘gastro-esophageal reflux’ OR ‘gastro-oesophageal reflux’ OR ger:ab,ti 
OR gerd:ab,ti OR gord:ab,ti AND (‘magnetic sphincter augmentation’ OR msa:ab,ti 
OR msad:ab,ti OR magnetic NEAR/4 (bead* OR band* OR ring OR device*) OR 
(‘magnet’/exp AND ‘therapy’/lnk) OR ‘anti reflux implant’/exp OR ‘lower esophagus 
sphincter’/exp/dm_su OR ‘esophageal sphincter’ NEAR/7 (device* OR ring* OR 
band* OR bead*) OR ‘oesophageal sphincter’ NEAR/7 (device* OR ring* OR band* 
OR bead*) OR (implant* OR insert*) NEAR/4 (sphincter* OR ring* OR bead* OR 
band* OR device*) OR ‘reflux management’ OR ‘antireflux management’ OR linx) 
AND (‘clinical trial’/de OR ‘clinical trial (topic)’/de OR ‘comparative effectiveness’/de 
OR ‘comparative study’/de OR ‘controlled clinical trial’/de OR ‘controlled study’/de 
OR ‘major clinical study’/de OR ‘multicenter study’/de OR ‘prospective study’/de 
OR ‘randomized controlled trial’/de OR’randomized controlled trial (topic)’/de) 
104 14 Dec 2015 
#24 ‘gastroesophageal reflux’/exp OR ‘gastroesophageal reflux’ OR ‘gastrooesophageal 
reflux’ OR ‘gastro-esophageal reflux’ OR ‘gastro-oesophageal reflux’ OR ger:ab,ti 
OR gerd:ab,ti OR gord:ab,ti AND (‘magnetic sphincter augmentation’ OR msa:ab,ti 
OR msad:ab,ti OR magnetic NEAR/4 (bead* OR band* OR ring OR device*) OR 
(‘magnet’/exp AND ‘therapy’/lnk) OR ‘anti reflux implant’/exp OR ‘lower esophagus 
sphincter’/exp/dm_su OR ‘esophageal sphincter’ NEAR/7 (device* OR ring* OR 
band* OR bead*) OR ’oesophageal sphincter’ NEAR/7 (device* OR ring* OR band* 
OR bead*) OR (implant* OR insert*) NEAR/4 (sphincter* OR ring* OR bead* OR 
band* OR device*) OR ‘reflux management’ OR ‘antireflux management’ OR linx) 
392 14 Dec 2015 
#23 ‘magnetic sphincter augmentation’ OR msa:ab,ti OR msad:ab,ti OR magnetic 
NEAR/4 (bead* OR band* OR ring OR device*) OR (‘magnet’/exp AND ‘therapy’/ 
lnk) OR ‘anti reflux implant’/exp OR ‘lower esophagus sphincter’/exp/dm_su OR 
‘esophageal sphincter’ NEAR/7 (device* OR ring* OR band* OR bead*) OR 
‘oesophageal sphincter’ NEAR/7 (device* OR ring* OR band* OR bead*) OR 
(implant* OR insert*) NEAR/4 (sphincter* OR ring* OR bead* OR band* OR 
device*) OR ‘reflux management’ OR ‘antireflux management’ OR linx 
52,993 14 Dec 2015 
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#22 linx  99 14 Dec 2015 
#21 ‘antireflux management’  7 14 Dec 2015 
#20 ‘reflux management’  75 14 Dec 2015 
#19 (implant* OR insert*) NEAR/4 (sphincter* OR ring* OR bead* OR band* OR device*) 35,158 14 Dec 2015 
#18 ‘oesophageal sphincter’ NEAR/7 (device* OR ring* OR band* OR bead*) 15 14 Dec 2015 
#17 ‘esophageal sphincter’ NEAR/7 (device* OR ring* OR band* OR bead*) 73 14 Dec 2015 
#16 ‘lower esophagus sphincter’/exp/dm_su  385 14 Dec 2015 
#15 ‘anti reflux implant’/exp  35 14 Dec 2015 
#14 ‘magnet’/exp AND ‘therapy’/lnk  276 14 Dec 2015 
#13 magnetic NEAR/4 (bead* OR band* OR ring OR device*) 11,732 14 Dec 2015 
#12 msad:ab,ti  66 14 Dec 2015 
#11 msa:ab,ti  5,559 14 Dec 2015 
#10 ‘magnetic sphincter augmentation’  45 14 Dec 2015 
#9 ‘gastroesophageal reflux’/exp OR ‘gastroesophageal reflux’ OR ‘gastrooesophageal 
reflux’ OR ‘gastro-esophageal reflux’ OR’gastro-oesophageal reflux’ OR ger:ab,ti 
OR gerd:ab,ti OR gord:ab,ti 
54,873 14 Dec 2015 
#8 gord:ab,ti  1,030 14 Dec 2015 
#7 gerd:ab,ti  11,163 14 Dec 2015 
#6 ger:ab,ti  3,902 14 Dec 2015 
#5 ‘gastro-oesophageal reflux’  4,729 14 Dec 2015 
#4 ‘gastro-esophageal reflux’  2,355 14 Dec 2015 
#3 ‘gastrooesophageal reflux’  501 14 Dec 2015 
#2 ‘gastroesophageal reflux’  44,392 14 Dec 2015 
#1 ‘gastroesophageal reflux’/exp  48,258 14 Dec 2015 
 
 
Search strategy for Medline 
Database: Ovid MEDLINE(R) <1946 to November Week 3 2015>, Ovid MEDLINE(R) In-Process &  
Other Non-Indexed Citations <December 10, 2015>, Ovid MEDLINE(R) Daily Update <November 18, 2015>,  
Ovid OLDMEDLINE(R) <1946 to 1965> 
Search Strategy: 
1 exp Gastroesophageal Reflux/(23190) 
2 gastro?esophageal reflux.mp. (27494) 
3 gastro-?esophageal reflux.mp. (1293) 
4 GER.mp. (3077) 
5 GERD.mp. (6391) 
6 GORD.mp. (719) 
7 1 or 2 or 3 or 4 or 5 or 6 (30135) 
8 Magnetic Sphincter Augmentation*.mp. (24) 
9 MSA.mp. (4137) 
10 MSAD.mp. (48) 
11 (magnetic adj10 (bead* or band* or ring or device*)).mp. (8998) 
12 exp Magnets/(5405) 
13 “Therapeutic Use”.fs. (1932854) 
14 12 and 13 (258) 
15 exp *Esophageal Sphincter, Lower/su (139) 
16 (esophageal sphincter adj10 (device* or ring* or band* or bead*)).mp. (58) 
17 (oesophageal sphincter adj10 (device* or ring* or band* or bead*)).mp. (14) 
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18 ((implant* or insert*) adj10 (sphincter* or ring* or bead* or band* or device*)).mp. (30855) 
19 exp “Prostheses and Implants”/(418917) 
20 exp Esophageal Sphincter, Lower/(816) 
21 esophageal sphincter*.mp. (5195) 
22 oesophageal sphincter*.mp. (1215) 
23 exp Esophagogastric Junction/(7352) 
24 gastro?esophageal junction*.mp. (2029) 
25 gastro-?esophageal junction*.mp. (194) 
26 esophagogastric junction*.mp. (7238) 
27 esophago-gastric junction*.mp. (171) 
28 oesophagogastric junction*.mp. (223) 
29 oesophago-gastric junction*.mp. (84) 
30 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 (12593) 
31 19 and 30 (333) 
32 reflux management.mp. (45) 
33 antireflux management.mp. (5) 
34 8 or 9 or 10 or 11 or 14 or 15 or 16 or 17 or 18 or 31 or 32 or 33 (44446) 
35 7 and 34 (272) 
36  ((randomized controlled trial or controlled clinical trial).pt. or randomi#ed.ab. or placebo.ab. or drug 
therapy.fs. or randomly.ab. or trial.ab. or groups.ab.) not (exp animals/not humans.sh.) (3213876) 
37  (((comprehensive* or integrative or systematic*) adj3 (bibliographic* or review* or literature)) or (meta-analy* 
or metaanaly* or “research synthesis” or ((information or data) adj3 synthesis) or (data adj2 extract*))).ti,ab. 
or (cinahl or (cochrane adj3 trial*) or embase or medline or psyclit or (psycinfo not “psycinfo database”) or 
pubmed or scopus or “sociological abstracts” or “web of science”).ab. or (“cochrane database of systematic 
reviews” or evidence report technology assessment or evidence report technology assessment summary).jn. 
or Evidence Report: Technology Assessment*.jn. or ((review adj5 (rationale or evidence)).ti,ab. and 
review.pt.) or meta-analysis as topic/or Meta-Analysis.pt. (259207) 
38 36 or 37 (3371568) 
39 35 and 38 (67) 
40 remove duplicates from 39 (66) 
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